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CRC                      colorectal cancer 
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ESI-MS                 electrospray ionization mass spectrometry 
ETD                      electron transfer dissociation 
FASP                    filter aided sample preparation 
FDA                      food and drug administration 
Ft                          ferritin 
FT                         Fourier transform 
FT-ICR                 Fourier transform ion cyclotron resonance 
GSH                      glutathione 
HSA                      human serum albumin 
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SUMMARY 
 
 
In this PhD thesis, mass spectrometry-based approaches were used to characterize, at 
molecular level, the adducts formed between some metallodrugs (or novel, promising 
metal compounds) and several proteins. Valuable information were gained about the 
chemical nature, the binding stoichiometry and the binding site location of the adducts 
formed. The obtained results can be profitably exploited for a more rational design of 
novel anticancer metallodrugs through a “mechanism oriented” approach. 
 
The whole work was organized into seven distinct chapters, as detailed below. 
 
In chapter 1 we reported a general review on the use of metals as anticancer agents, 
from the past years to present days, focusing the attention on platinum, ruthenium and 
gold compounds. The importance of studying metal-based anticancer drug/protein 
interactions was discussed and the key role of MS in this field was highlighted. 
 
In chapter 2, first of all we described the past studies performed in our laboratories, 
which constitute the research background of this project. Then, we explained the aims 
of this PhD thesis, pursued through two main search directions: 
i) the survey on the chemical nature and the binding stoichiometry of the adducts 
formed between small size proteins and: a) new analogues of cisplatin and oxaliplatin 
anticancer drugs (chapter 3); b) novel Au(III) complexes (chapter 4); 
ii) the development and introduction in our laboratories of an efficient and generally 
applicable method for metallodrugs binding site location on proteins, regardless of the 
MW and nature of the protein and the type of metal complex under investigation, in 
order to get closer to the study of real, interesting biological systems (chapters 5 and 
6). 
 
In chapter 3, the chemical and biological profiles of the novel complexes cisPtBr2 and 
PtI2(DACH) were studied in comparison to those of their precursors, respectively 
cisplatin and oxaliplatin. 
In chapter 4, analogues studies were performed on Au(III) complexes bearing chelating 
nitrogen/carbon donors or quinoline derivatives as N-/O-donors. 
A detailed discussion was carried out on the ESI-MS results obtained by studying the 
interactions of these metal compounds with the model proteins HEWL, RNase A, Cyt c 
and Atox1. The importance of the information obtained about the chemical nature and 
the binding stoichiometry of the metallo fragments, as well as on the oxidation state of 
the metal center, was discussed. 
 
6 
 
In chapter 5, we reported the design and the application of a general and systematic 
protocol to test, a priori, the stability of metallodrug-protein adducts under the typical 
conditions of the FASP/bottom-up mass spectrometry approach, being this latter the 
methodology we chose for the binding site location studies described in chapter 6. The 
protocol was specifically applied to two representative model systems, the more 
investigated Cyt c-CDDP adducts and the less studied Cyt c-RAPTA-C ones. The 
different obtained results highlighted the advisability to perform a test-protocol like 
this when starting any bottom-up MS investigation on protein-metallodrug systems, 
especially with novel, or scarcely studied, metal complexes. 
 
In chapter 6, we applied, for the first time in our laboratories, the FASP/bottom-up MS 
approach for cisplatin binding site location on the model protein Cyt c and the actual 
target protein HSA. 
For the CDDP-Cyt c system we obtained results in good agreement with those already 
present in the literature. The FASP/bottom-up approach proved its capability to 
highlight the selective binding of CDDP to Cyt c, and it also demonstrated its 
extensibility, in a systematic way, to other simple, model systems endowed of the 
needed stability. Moreover, we discussed in detail all the critical issues related to the 
lack of specific softwares for metalloproteomics data analysis. 
The application of the FASP/bottom-up MS approach to the more complex system 
CDDP-HSA produced results which do not find a match with those reported in the 
literature, already poorly concordant with each other. The possible causes of this 
discrepancy were discussed. Finally, we declared the advisability of a more detailed 
investigation on the CDDP-HSA system before attempting to extend the methodology, 
in a systematic way, to other proteins of large size. 
 
In chapter 7 we presented the general conclusions and we proposed possible future 
research topics to be developed.  
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1. INTRODUCTION 
 
 
1.1 Anticancer metallodrugs 
 
1.1.1 Metal complexes with pharmacological properties 
The pharmaceutical use of metal complexes has an excellent potential. A broad array 
of medicinal applications of metal complexes has been investigated, and several recent 
reviews summarize advances in these fields [1-3]. Now the list of therapeutically 
prescribed metal containing compounds includes platinum (anticancer), silver 
(antimicrobial), gold (antiarthritic), bismuth (antiulcer), antimony (antiprotozoal), 
vanadium (antidiabetic) and iron (antimalarial). Metal ions are electron deficient, 
whereas most biological molecules (DNA, proteins) are electron rich; consequently, 
there is a general tendency for metal ions to bind to and interact with many important 
biological targets. These considerations alone have fueled much of the past and current 
interest in developing novel means to use metals or metal containing agents to 
modulate biological systems. 
In general, a metal complex that is administered, is likely to be a “prodrug” that 
undergoes an in vivo transformation before reaching its target site. Most importantly, 
the biological properties of metal complexes depend not only on the metal nature and 
its oxidation state but also on its ligands, which can render either the whole complex 
inert to ligand substitution reactions or can activate other coordination positions 
stereospecifically. Besides the metal itself, the ligands can also be the centers of redox, 
hydrolytic or other reactions. 
Medicinal inorganic chemistry is a relatively young, interdisciplinary research field 
and the rational design of metal-based drugs is a relatively new concept too. 
Developing metal complexes as drugs, however, is not an easy task. Accumulation of 
metal ions in the body can lead to very deleterious effects. Thus, biodistribution and 
clearance of metal complex, as well as its pharmacological specificity, have to be 
carefully considered. Favorable physiological responses of the candidate drugs need to 
be demonstrated by in vitro studies with targeted biomolecules and tissues, as well as 
in vivo investigation with xenografts and animal models, before they may enter clinical 
trials. A mechanistic understanding on how metal complexes produce their biological 
activities is crucial to their clinical success, as well as to the rational design of new 
compounds with lower toxicity and improved potency. 
 
1.1.2 Metal-based anticancer drugs 
The modern era of metal-based anticancer drugs began with the serendipitous 
discovery of cisplatin by Rosenberg and co-workers in the late 1960s. Stimulated by 
Chapter 1 
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the success of cisplatin, cisplatin analogues, as well as other coordination compounds 
based on ruthenium, gold, titanium, copper, rhodium, vanadium and cobalt, were tested 
for their anticancer activities and several promising candidates are currently in 
(pre)clinical evaluation [4-10]. 
Of particular interest is the elucidation of the mechanism of action of the various non-
platinum metal complexes and the investigation of their final targets. Indeed, while 
several data are now available regarding the mechanism of Pt(II) compounds, limited 
work has been done on the mechanism of action of non-platinum metal complexes 
which exhibit encouraging cytotoxicity and antitumor activity profiles. 
Among non-platinum antitumor metal complexes there are two groups of compounds 
which deserve special attention: these are the ruthenium and gold complexes. For 
example, contrary to cisplatin, the Ru(III) complex called NAMI-A has a unique 
feature, namely a higher activity against metastases than against primary tumors [11]. 
Moreover, at variance with platinum complexes, it is noteworthy to mention that DNA 
seems not to be the primary cellular target mediating the antitumor activity for most 
non-platinum metal-based drugs [11,12]. 
 
1.1.3 Platinum-based anticancer drugs 
The interest in platinum-based antitumor drugs has its origin in the 1960s, when 
Rosenberg observed the inhibition of E. coli cell division induced by Pt complexes 
[13]. 
Since then, thousands of platinum compounds have been prepared and evaluated as 
potential chemotherapeutic agents, although few have entered clinical use (fig. 1.1). 
 
Fig 1.1 Chemical formulae of the worldwide approved platinum anticancer drugs 
cisplatin, carboplatin and oxaliplatin. 
 
Cisplatin (fig. 1.1), a square planar Pt(II) complex (d8, diamagnetic, dsp2 
hybridization), is highly effective against a number of cancer types, especially 
testicular cancer, for which it has a greater than 90 % cure rate [14].  
Despite its clinical success, there are several disadvantages associated with cisplatin, 
such as low water solubility [15], significant toxicity, which limits patient doses [15], 
Pt
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severe side effects such nausea, nephrotoxicity, neurotoxicity [16] and intrinsic or 
acquired resistance in some cancer types [17,18].  
Cisplatin is generally believed to exert its anticancer effect by interacting with DNA 
and inducing programmed cell death (apoptosis) [17,19,20]. Following intravenous 
administration, cisplatin encounters a relatively high chloride concentration in blood 
flow (approximately 100 mM) that limits replacement of its chloride ligands by water 
molecules, thus preventing aquation process [14]. However, cisplatin is vulnerable to 
attack by proteins found in the blood plasma, particularly by those that contain thiol 
groups, such as human serum albumin [21,22]. In fact, studies have shown that one day 
after cisplatin administration, 65-98 % of Pt in the blood plasma is protein bound [23]. 
This protein binding has been blamed for the deactivation of the drug and for some of 
the severe side effects of cisplatin treatment. The intact cisplatin can enter tumor cells 
mainly by passive diffusion through the cell membrane, although facilitated or 
activated transport mechanisms may contribute to the cellular uptake as well [17,18]. 
The intracellular chloride concentration is relatively low (approximately 4-20 mM); 
hence one of the chloride ligand of the intact complex is rapidly replaced by water, 
forming the reactive, positively charged species [(NH3)2PtCl(H2O)]+ (scheme 1.1) that 
cannot readily leave the cell [24]. Cisplatin, as well as the most part of metallodrugs, 
acts here as a “prodrug”, in other words an activation step is required before it can 
react with its biomolecular targets and cause its specific biological effects. 
 
Scheme 1.1 Hydrolysis reactions of CDDP. 
 
This monoaquated platinum species is predominant in cytoplasm [25] and reacts with 
one of the DNA bases, usually guanine, forming monofunctional DNA adducts. Ring 
closure to form a bifunctional adduct with the nucleic acid may occur, either directly 
from the monofunctional adduct or may involve aquation of the second chloride ligand 
followed by rapid closure [26,27]. The major site of platination in DNA derives from 
1,2-intrastrand crosslinks between two neighboring guanines but 1,3-intrastrand 
crosslinks are also possible (fig. 1.2) [28]. 
 
 
 
[(NH3)2PtCl2] [(NH3)2PtCl(H2O)]
+ [(NH3)2Pt(H2O)2]
2+
- Cl- - Cl-
+ Cl-+ Cl-
[(NH3)2PtCl(OH)]
+ H+ - H+
[(NH3)2Pt(OH)2]
+ 2H+ - 2H+
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Fig 1.2 Cisplatin undergoes aquation to form [Pt(NH3)2Cl(OH2)]+ and 
[Pt(NH3)2(OH2)2]2+ once inside the cell. The platinum atom of cisplatin binds 
covalently to the N7 position of guanines to form 1,2- or 1,3-intrastrand crosslinks, and 
interstrand crosslinks (figure taken from “D. Wang, S. J. Lippard, Nat. Rev. Drug 
Discov., 2005, 4, 307-320”). 
 
The formation of covalent crosslinks between cisplatin and the DNA double helix 
causes a significant distortion of the helical structure and results in inhibition of DNA 
replication/transcription thus leading to cytotoxicity [17,29,30].  
However, the effectiveness of CDDP treatment is greatly limited by the phenomenon 
of tumor resistance. Several tumors are intrinsically resistant to cisplatin while others 
acquire resistance after exposure to the drug over time. The cellular mechanism of 
CDDP resistance has been identified as decreased intracellular accumulation (the 
mechanism is not clear but the cell has probably some control over the entering of 
cisplatin, thus suggesting that this drug does not enter the cell by passive diffusion 
alone but that some active transport system may be involved) [31], strong binding to 
inactivating sulphur–containing molecules inside the cell (MTs and GSH) [32] and 
increased repair of platinated DNA by enzymes [33]. 
Researchers have focused attention on designing new platinum compounds with 
improved pharmacological properties and a broader range of antitumor activity. In 
general, for a platinum drug to gain clinical approval, it must possess at least one 
distinct clinical advantage over cisplatin. Such advantage may include: activity against 
cancers with intrinsic or acquired resistance to CDDP, reduced toxic side effects or the 
ability to be orally administered. Several platinum complexes are currently in clinical 
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trials but these new complexes have not yet demonstrated significant advantages over 
cisplatin [34]. 
Carboplatin and oxaliplatin (fig. 1.1) are considered the main exponents, respectively, 
of the second- and third-generation platinum anticancer drugs. 
In carboplatin [35] the two chloride ligands are replaced with the bulkier 
cyclobutanedicarboxylate bidentate ligand. The spectrum of the biological action of 
carboplatin substantially reproduces that of cisplatin, implying an identical mechanism 
of action [28,35,36], but carboplatin manifests a more favorable toxicological profile 
than cisplatin itself. The reasons of this lie in the fact that the aquation process of 
carboplatin is far slower than in the case of CDDP: studies on the interaction of 
carboplatin with small molecules or peptides containing sulphur indicated that this 
reaction proceeds via ring-opening of the cyclobutanedicarboxylate ligand, thus 
lowering the rate of the aquation and thereby the reactivity of the compound [37].  
Oxaliplatin [35,37] is the only platinum compound to have displayed activity against 
colorectal cancer so far [38,39]. The chemical structure of oxaliplatin differs from 
those of cisplatin and carboplatin by the attachment of a cyclohexane ring to the 
nitrogen atoms. It is a compound with relatively good water solubility; it achieved 
good efficacy in experimental tumor models and displayed low haematological toxicity 
and minimal or no nephrotoxicity in preclinical studies [39]. Oxaliplatin shows 
comparable chemical behavior and has a similar mechanism of action as compared to 
the previous platinum derivatives, but its hydrolysis process (displacement of the 
oxalate group) is slower than for cisplatin [40]. 
Other noteworthy Pt-compounds are [35]: trans-platinum, polynuclear platinum and 
platinum(IV) complexes. In particular, the latter have good prospect for oral 
administration so that the quality of life of cancer patients could be improved avoiding 
the upsetting effects of intravenous administration of Pt-drugs. It is generally believed 
that platinum(IV) complexes are reduced to platinum(II) by extracellular and 
intracellular agent prior to reaction with DNA, thus acting as a “pro-drug” through a 
redox activation process.   
 
1.1.4 Ruthenium anticancer agents 
Ruthenium complexes have attracted interest for their potential use as anticancer 
agents in the past 30 years [41,42]. In detail, ruthenium compounds show low systemic 
toxicity and appear to enter the tumor cells, to bind effectively DNA and proteins and 
to manifest, in some cases, selective antimetastatic properties. 
There are three main properties that make ruthenium compounds well suited for 
medical applications [43]: i) the range of accessible oxidation states, ii) the ability to 
mimic iron in binding to many biological molecules, iii) the rate of ligand exchange. 
For anticancer ruthenium complexes, at variance with platinum drugs, two different 
accessible oxidation states are possible under physiological conditions: Ru(II) (d6, 
Chapter 1 
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diamagnetic, d2sp3 hybridization) and Ru(III) (d5, paramagnetic, d2sp3 hybridization). 
Therefore, the ruthenium complexes are redox-active agents that can undergo electron-
transfer reactions with biological reactants. For example, the drug can be administered 
as relatively inert Ru(III) complex, which is activated by reduction in diseased tissues. 
In fact, in many cases, the altered metabolism associated with cancer, results in a lower 
oxygen concentration in these tissues, compared to healthy ones, and this promotes a 
reductive environment. 
The ability of ruthenium compounds to mimic iron in binding to certain biological 
molecules, including serum proteins (e.g., transferrin and albumin), is believed to 
contribute to the general low toxicity of ruthenium drugs. Moreover, the high iron 
requirement of tumor cells results in the expression of a large number of receptors for 
the iron transport protein transferrin which is believed to result in the accumulation of 
Ru(III) complexes in tumors. Transferrin is thought to act like a ‘‘Trojan Horse’’, 
transporting the Ru-complex instead of or in addition to the required iron into the cell 
[6].  
Many Ru(II) and Ru(III) complexes have been evaluated for clinical applications due 
to their kinetics of ligand exchange, similar to those of Pt(II) compounds. Ligand 
exchange is an important characteristic for biological activity as very few metal drugs 
reach the biological target without being modified. 
Finally, Ru(II) and Ru(III) complexes, at variance with square planar Pt(II) 
compounds, are characterized by an octahedral geometry and this may suggest 
different manners of action. 
The first ruthenium agent to enter clinical trials in 1999 was NAMI-A [44] (fig 1.3).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.3 Chemical formulae of ruthenium compounds NAMI-A, KP1019 and RAPTA-
C. 
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NAMI-A (-A suffix indicates that this is the first of a potential series) binds DNA and 
produces effects similar to those of cisplatin but, unlike cisplatin, only at relatively 
high concentrations. Interestingly, NAMI-A turned out to be a potent agent against 
solid tumor metastases. This is potentially very important because, although great 
progresses have been made in treating primary cancers (including surgery, 
chemotherapy and radiotherapy), secondary metastases still represent a major clinical 
challenge. The antimetastatic effect of NAMI-A is likely due to either interference with 
specific proteins involved in signal transduction pathway or altered cell adhesion 
processes [45,46]. NAMI-A binds also transferrin, an event which is supposed to target 
the compound to cancer cells. 
The second Ru(III) compound currently in clinical trials is KP1019 [6] (fig. 1.3). This 
compound was developed by Keppler and co-workers and, despite its structural 
similarity to NAMI-A, is active against primary tumors. The mode of action of 
KP1019 probably involves accumulation in transferrin receptor-(over)expressing tumor 
cells via the transferrin receptor, subsequent reduction to Ru(II) species, reaction with 
DNA (with a preference shown for G and A residues) and induction of apoptosis via 
the intrinsic mitochondrial pathway. KP1019 binding with human serum albumin in 
the blood stream has also been proved and is believed to provide a ‘‘reservoir’’ for the 
drug. 
More recently, another class of ruthenium anticancer agents, named RAPTA, has been 
developed by Dyson and co-workers [45]. The RAPTA family is characterized by the 
presence of a Ru center (R), a 6-arene tridentate ligand (A) and a 1,3,5-triaza-7-
phosphadamantane monodentate ligand (PTA). The RAPTA compounds have piano-
stool geometry and the remaining two coordination sites can be occupied by two 
chlorides or other ligands. The compounds of general formula [Ru(6-arene)Cl2(pta)], 
the prototype being [Ru(6-p-cymene)Cl2(pta)] (RAPTA-C) (fig. 1.3), were developed 
in order to create pH-dependent DNA-damaging agents but they resulted to be only 
poorly toxic towards cancer cells in vitro [11]. Like NAMI-A, these agents are inactive 
against primary tumors but they show activity against metastases in vivo [11]. As 
NAMI-A, the indications are that proteins, rather than DNA, are the biomolecular 
targets for action of the drug. 
 
1.1.5 Gold complexes as antitumor agents 
Gold compounds have a long and important tradition in medicine and they were widely 
used in early times of modern pharmacology for the treatment of several diseases, 
especially as anti-infective and antitubercular agents [47]. Nowadays, gold compounds 
find rather limited medical application and are presently used only for the treatment of 
severe rheumatoid arthritis [48]. This is probably the result of relevant systemic 
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toxicity (e.g., nephrotoxicity) and of the poor chemical stability of some of the tested 
compounds. 
Remarkably, during the last two decades, a large number of Au(I) and Au(III) 
compounds have been reported to show relevant antiproliferative properties in vitro 
against selected human tumor cell lines, qualifying themselves as excellent candidates 
for further pharmacological evaluation [49–52].  
Gold can exist in a number of oxidation states, but apart from Au(0) in the colloidal 
and elemental forms, only Au(I) and Au(III) give rise to compounds reasonably stable 
in aqueous/biological environments. In any case, both Au(I) and Au(III) are 
thermodynamically unstable with respect to Au(0) and are, thus, readily reduced to 
elemental gold by mild reducing agents. Au(I) is more stable than Au(III); accordingly, 
Au(III) complexes are generally strong oxidizing agents and potentially toxic in 
biological systems, where their reduction can be driven by biologically occurring 
reducing agents such as thiols. Au(I) has a d10 closed-shell configuration that gives rise 
to three main coordination geometries: linear two-coordination (by far the most 
common, sp hybridization), trigonal three-coordination (sp2 hybridization) and 
tetrahedral four-coordination (sp3 hybridization). Instead, Au(III) compounds typically 
adopt a tetra-coordinate square planar geometry (d8, diamagnetic, dsp2 hybridization) 
as Pt(II). While Au(I) is a “soft” cation, and shows preference for “soft” ligands (e.g., 
S, Se, cyanide, etc.), Au(III) is a “borderline” cation showing a preference for soft 
ligands but also for nitrogen donors [53]. 
Gold(I) anticancer compounds are divided into two classes (fig. 1.4):  
(i) Au(I) phosphine compounds, such as the linear two-coordinated auranofin and the 
tetrahedral four-coordinated [Au(dppe)2]Cl; 
(ii) Au(I) NHCs complexes.  
There are evidences that both classes of compounds act by mechanisms involving 
mitochondrial cell death pathways [54]. 
The aqueous solution chemistry of auranofin has been intensively investigated [55,56] 
and indicates that thiolate ligands are usually more labile than phosphine ligands and 
undergo rapid aquation. The resulting cationic species usually show a strong reactivity 
with biomolecules containing thiol groups, thus limiting its antitumor activity in vivo. 
Auranofin has been shown to induce apoptosis via selective inhibition of the 
mitochondrial isoform of thioredoxin reductase, an enzyme involved in the thiol redox 
balance in cell and up-regulated in malignant diseases. This inhibition is attributable to 
the binding of Au(I) to the redox-active selenocysteine residue of TrxR: the 
selenocysteine group, in the reduced form, displays a high reactivity toward “soft” 
metal ions [54]. 
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Fig 1.4 Chemical formulae of auranofin, [Au(dppe)2]Cl and some examples of Au(I)-
NHC complexes. 
 
In order to reduce the high thiol reactivity of linear two-coordinated Au(I) compounds, 
investigations were carried out on Au(I) complexes with chelate diphosphines: for 
example, [Au(dppe)2]Cl showed to exhibit significant antitumor activity against a 
range of model tumors in mice [57]. However, due to the severe hepatotoxicity 
observed in dogs [54], this compound was abandoned. The antitumor activity of 
tetrahedral Au(I) phosphine complexes may stem from the lipophilic, cationic 
properties of these compounds, as for other delocalized lipophilic cations that 
accumulate in mitochondria [54]. 
Many studies have shown that NHCs ligands have similar properties to phosphines in 
the way they interact with metals, including gold. These similarities led the researchers 
to investigate on Au–NHC complexes as potential new antitumour agents. For this 
class of compounds, a mechanism of action targeting mitochondria and involving TrxR 
inactivation is supposed, too [54]. 
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Since Au(III) complexes are isoelectronic and isostructural with Pt(II) compounds (d8, 
diamagnetic, dsp2 hybridization, tetra-coordinate square planar geometry), soon they 
seemed to be excellent and innovative candidates for anticancer testing. However, at 
variance with Pt(II) compounds, Au(III) complexes were readily found to manifest a 
rather poor stability profile being kinetically more labile than the corresponding Pt(II) 
compounds, light-sensitive and easily reducible to metallic gold. As a results of these 
difficulties and, also, of detection of important in vivo toxicity, Au(III) compounds 
were quickly abandoned. Nonetheless, during the 90’s, there was a strong return of 
interest toward gold(III)-based compounds as anticancer agents, especially when a few 
novel Au(III) complexes exhibiting improved stability, lower toxicity and favourable 
in vitro and in vivo pharmacological properties [49], were prepared. 
A vast array of Au(III) complexes showing rather variegated structural chemistry has 
been considered as potential anticancer drugs [58]. From a structural point of view, the 
gold(III) compounds of interest may be grouped into the four following classes [59] 
(fig. 1.5):  
(i) classical mononuclear gold(III) complexes. These compounds are square planar 
gold(III) compounds accompanied with nitrogen or halide ligands: [AuCl4]-, 
[Au(dien)Cl]Cl2, [Au(en)2]Cl3, [Au(cyclam)](ClO4)2Cl, [Au(terpy)Cl]Cl2 and 
[Au(phen)Cl2]Cl. Nitrogen ligands are less labile than chloride ligands, while chloride 
ligands undergo far more facile aquation reactions. In turn, nitrogen ligands induce 
significant stabilization of the oxidation state +3; 
(ii) gold(III) porphyrins. The porphyrin ligand greatly stabilizes the Au(III) center and 
drastically reduces its redox reactivity and oxidizing character. Reduction of gold(III) 
to gold(I) or elemental gold is very rare; 
(iii) organogold(III) compounds. These complexes have at least one direct carbon–
gold(III) bond which stabilizes oxidation state of gold. Organogold(III) compounds are 
stable under physiological conditions and have a limited tendency to be reduced to 
gold(I). They are significantly cytotoxic to human tumor cell lines; 
(iv) dinuclear gold(III) complexes. These complexes are very stable under 
physiological-like conditions and have significant antiproliferative effects toward 
different human tumor cell lines. All these compounds contain a common structural 
motif, consisting of an Au2O2 “diamond core” linked to two bipyridine ligands in a 
roughly planar arrangement. Importantly, the introduction of different alkyl or aryl 
substituents on the 6 (and 6’) position(s) of the bipyridine ligand leads to small 
structural changes that greatly affect the reactivity of the metal centers. 
Advanced pharmacological testing performed with various gold (III) compounds 
suggests a mechanism that is distinct from classical platinum(II) compounds. Even 
though some evidence for direct DNA damage has been obtained in a few cases, 
effects on nucleic acids appear to be very modest for Au(III) complexes, so that it is 
unlikely that DNA is their primary target [60]. Instead, as in the case of auranofin, a 
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mechanism of action causing direct mitochondrial damage through selective 
modification of the active selenol site in TrxR is supposed [54]. 
 
 
Fig 1.5 Representative Au(III) compounds belonging to classes (i)-(iv). 
 
1.1.6 The importance of studying metal-based anticancer drug/protein interactions 
During the last four decades, the interest of the scientific community working on 
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the commonly accepted primary target for platinum compounds, that were described 
and analyzed in hundreds of papers [20]. 
In contrast, the reactions of platinum and non-platinum anticancer metallodrugs with 
proteins have initially received very poor attention but this topic is now attracting more 
and more interest. It is in fact increasingly evident that the interactions of anticancer 
metallodrugs with proteins play crucial roles not only in their uptake and 
biodistribution processes, but also in determining their overall toxicity profile, as for 
example in the case of Pt-drugs and the two major serum proteins albumin and 
transferrin [61-65]. Moreover, the inactivation of metallodrugs, and the resistance 
phenomena to metallodrugs, can be related to metal complex interaction with proteins, 
as in the case of cisplatin and metallothioneins, low molecular weight cysteine-rich 
proteins mainly involved in soft metal ion detoxification process [66]. Even more 
interesting, anticancer metallodrug-protein interaction has demonstrated to be likely 
involved in some crucial aspects of the mechanism of action of specific antitumor 
agents, as already mentioned in paragraphs 1.1.4 and 1.1.5, respectively, for Ru and Au 
compounds.  
Thus, further work is absolutely needed to better understand the reactions of 
metallodrugs with proteins at the molecular level, in order to identify common trend in 
these reactions, characterize the structure and reactivity of the resulting “adducts” (in 
which the metallic fragment is coordinatively bound to protein) and identify the most 
important intracellular protein targets for the various classes of anticancer 
metallodrugs. In fact, a mechanistic understanding of how metal complexes produce 
their biological activities is crucial to their clinical success, as well as to the rational 
design of new and more efficient drugs through a “mechanism oriented” approach. 
 
 
1.2 Mass spectrometry as a tool to study anticancer metallodrug-protein 
interactions 
 
1.2.1 An overview 
A combination of various techniques and approaches has been used for studying the 
biological effects of selected anticancer metallodrugs or novel transition metal 
complexes synthesized for application in therapy: chromatographic techniques (TLC or 
LC), mass spectrometry, nuclear magnetic resonance, microscopy, computational 
methods, capillary electrophoresis, isothermal titration calorimetry and differential 
scanning calorimetry, IR or UV/Vis spectroscopy, circular dichroism [67-69]. 
Despite of the abundance of available techniques, the gold standard for structural 
information on metallodrug-protein adducts at atomic resolution remains X-ray 
crystallography diffraction. The main challenge in XRD is sample preparation. 
Optimization of protein crystallization can be a lengthy process, if indeed it is 
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achievable at all [70]. Moreover, this technique provides only a static vision of metal 
complex-protein adducts in the solid state. 
To date NMR is the method of choice for data collection at molecular level in the 
liquid phase; however, it is time consuming, protein size limited and may only work 
effectively under solution or substrate concentration conditions that may be 
unfavorable for the formation of stable protein adducts and which do not mimic 
physiological conditions. Moreover, as for XRD, strict requirements on sample purity 
are mandatory. 
Mass spectrometry has been recognized as having great potential for the analysis of 
biomolecule/ligand adducts, due to its high sensitivity, specificity, high-throughput 
capability. The biological targets studied may include not only proteins but also 
enzymes and DNA [71] and the classes of ligands analyzed encompass not only 
anticancer metallodrugs but also peptides, proteins, nucleic acids, metal ions, drugs in 
general [72-75]. Through MS experiments valuable and independent structural 
information can be obtained in order to enrich and complete the data coming from the 
other analytical techniques. An example of the combined use of MS and X-ray 
crystallography can be found in a recent paper of Merlino and coworkers [76].  
 
1.2.2 Mass spectrometry ionization techniques for studying the interactions of 
metallodrugs with proteins 
In MS, the most common ionization techniques for studying the interactions of metal 
complexes with proteins are inductively-coupled plasma, electrospray ionization and 
matrix assisted laser desorption ionization. 
ICP-MS relies on the atomization and ionization of the sample in the plasma, thus 
generating mainly singly-charged positive metal ions which can be detected in the MS 
analyzer. Consequently, ICP-MS tends to be employed for the determination of total 
metal contents in biological samples but does not give structural information [77]. 
Instead, ESI [78] and MALDI [79,80] techniques have enabled scientists to observe ion 
species of intact proteins and intact metallodrug-protein adducts. These two ionization 
methods have widely been used and are essential in the structural study of biological 
molecules. The two techniques are so important that the inventors, John B. Fenn and 
Koichi Tanaka, shared a portion of the Nobel Prize in chemistry in 2002. 
ESI source was developed by Fenn and coworkers in 1984 [81] and is schematically 
represented in fig. 1.6 
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Fig. 1.6 A schematic illustration of ESI source developed by Fenn et al. in 1984 (figure 
taken from “S. Akashi, Med. Res. Rev., 2006, 26, 339–368”). 
This source generated ions in the gas phases at atmospheric pressure by spraying a 
sample solution from a metal needle where high voltage, such as + 3-4 kV, was 
applied. In addition, heated nitrogen gas helped to dry the sample droplets formed in 
the spraying process. A glass capillary was used as an orifice for transporting the ions 
from the ionization source at atmospheric pressure to the mass spectrometer under high 
vacuum. Several improvements have been accomplished based on the original ESI ion 
source, and now ESI mass spectra of various biological molecules can easily be 
obtained using commercially available instruments. ESI can generate ions with 
multiple charges, such as [M + nH]n+ (when positive voltage is applied to the needle) 
or [M - nH]n- (when negative voltage is applied to the needle). The molecular weight of 
the biomolecule under examination can be then automatically calculated by using a 
deconvolution software. 
Today, ESI-MS represents a very powerful method for molecular characterization of 
metal complex-biomolecule adducts. A series of pioneering studies carried out by Dan 
Gibson and coworkers during the 1990s and the early 2000s highlighted the advantages 
of this method and defined the experimental conditions for its application to investigate 
metallodrug-protein [82-84] or nucleobase [84] systems: information on the chemical 
nature of the adducts formed, the binding stoichiometry and the binding site location 
were obtained. ESI-MS can also provide information on binding specificity from 
competition experiments [85] and dissociation constants (Kd value) of protein-ligand 
complexes from titration experiments [86]. 
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Laser desorption is another ionization method that can generate molecular ion of 
biological macromolecules. During the 1980s, several groups tried to ionize non-
volatile molecules using lasers. In 1985, Hillenkamp and Karas [87] showed that 
aromatic matrix could be used to facilitate the volatilization of small molecules, but 
they did not succeed in ionization of biological macromolecules at that time. In 1987, 
Tanaka et al. [79] reported that large biomolecules could be ionized by a laser 
desorption method using a 337-nm low-energy (nitrogen) laser and a matrix of glycerol 
containing colloidal particles. They succeeded in ionization of intact proteins, and 
singly and doubly charged ions were detected. This was a breakthrough for the laser 
desorption method in its application to biological macromolecules. This technique has 
been mainly improved by Hillenkamp et al. as MALDI [80]. A schematic 
representation of MALDI is reported in fig. 1.7. 
 
 
 
Fig. 1.7 A schematic representation of MALDI process (figure taken from “S. Akashi, 
Med. Res. Rev., 2006, 26, 339–368”). 
In MALDI, the sample is co-crystallized on a target plate with a matrix compound, 
such as sinapinic acid, in about a 1:1,000 molar ratio. Laser desorption occurs when the 
sample is irradiated with a focused laser beam in the ion source of the mass 
spectrometer. Most of the energy from the 337 nm pulsed laser beam is first adsorbed 
by the matrix and then used for vaporization and ionization of both the matrix and 
analyte molecules. The exact mechanism of MALDI, however, is not completely 
understood. 
Since MALDI is robust and very tolerant of impurities in comparison to ESI, it is 
applicable to a large variety of compounds. However, there are only a limited number 
of reports on the detection of intact non-covalent complexes by MALDI-MS [88–94], 
because the dried sample mixed with the organic matrix is not ideal for the observation 
of non-covalent complexes that function under physiological conditions in solution 
phase. In addition, it is difficult to differentiate the ions of specific non-covalent 
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complexes from those of non-specific associations. Consequently, application of 
MALDI-MS to the detection of intact ions of non-covalent complexes is now far from 
being routine, and the literature on the ESI method for non-covalent complex analysis 
is now rapidly expanding [72]. Regarding specifically the strength of the coordinative 
bond between metallodrugs and protein, we have to say that it manifests an appreciable 
grade of stability under ESI conditions. Instead MALDI, though considered a soft 
ionization technique as ESI, can induce a certain degree of cleavage in metallodrug-
protein adducts, both at protein-metal and metal-ligand bond level [95,96]. However, a 
general behavior rule is not easily predictable and the stability of the metal-protein 
adducts to the ionization conditions must be evaluated/ascertained time by time, being 
it related to the nature of the metal, the type of complex and the protein chosen.  
 
1.2.3 High resolution mass analyzers for the study of metallodrug-protein adducts 
High resolution mass analyzers, such as the quadrupole-time of flight [97], the Fourier 
transform-based Orbitrap [98] and the FT-ion cyclotron resonance [99], represent the 
state-of-the-art instruments. The advent of this kind of analyzers, endowed with 
isotopic resolution and high mass accuracy (< 5 ppm), has made possible to 
characterize proteins and metallodrug-protein adducts without proteolytic digestion, 
but simply by the direct fragmentation of the whole molecule in the mass spectrometer 
and the accurate acquisition of the masses of the fragments and the intact protein (or 
adduct) [100-102]. This procedure is referred to as top-down approach. 
 
1.2.4 Mass spectrometry and metalloproteomics 
Metallomics encompasses metalloproteomics as well as metallometabolomics. It is an 
emerging field addressing the role, uptake, transport and storage of trace metals 
essential for protein functions, but can also focus on metallometabolites, which may 
appear in the environment or which circulate in organisms as metal carriers. In this 
frame, extrapolating, the study of the fate of metallodrugs inside the human body can 
be ascribed to metallomics field and, more specifically, to metalloproteomics if the 
interaction of the metal complexes concern proteins. 
The use of advanced protein separation techniques (e.g., LC, CE, 2DGE), coupled to 
very sensitive metal detection methods, hold promise for successful analysis of 
complex mixtures of metallated proteins and for identification of those proteins that act 
as primary metallodrug receptors and/or metallodrug target. Thus, these latter 
techniques open the way to the investigation of far more complicated systems, such as 
metallodrug-treated cell populations and/or cell homogenates, that reflect more closely 
the reality of metallic species in the cell world.  
ICP-MS, opportunely interfaced with a specific separation system, is a high specificity, 
high sensitivity technique. However, the derived data provide only information about 
the presence or absence of a specific metal element inside the biological sample, but it 
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will not allow any in-depth identification or characterization of the analyzed molecules 
[77]. 
The bottom-up MS approach, that is, metallodrug-protein adducts characterization by 
the combination of proteolytic digestion, LC separation and mass measurement, has 
successfully been applied on single protein, mixture of standard proteins and real 
samples (human blood serum, rat kidney cytosolic extracts, E. coli cells), in order to 
identify Pt- and Ru-bound proteins and the nature and position of the metallo 
fragments formed. In these experiments the classical bottom-up approach: 
i) was applied as such [103]; 
ii) was preceded by laser ablation inductively coupled plasma mass spectrometry (LA-
ICP-MS) on 1D or 2D gels in order to identify the bands/spots containing Pt [104,105]; 
iii) exploited a multidimentional protein identification technology (MudPIT) that 
combines SCX and RP chromatography [106-108]; 
iv) was applied only to the Pt-containing fractions obtained by a peptide or protein pre-
fractionation step in OFFGEL-IEF [109,110]; 
v) exploited the ion mobility separation technique [111]. 
Mass spectrometry reveals to be a powerful technique for the analysis of complex 
mixtures in the molecular profiling approach, too. This approach gives an overview on 
alterations in protein expression between different cell states as, for example, the 
protein profile regulation in colon carcinoma cell lines treated with different 
metallodrugs (label-free quantitative proteomic approach) [112].  
Finally, the recent advancements in data handling software, MS instrumentation and 
histological sample preparation make possible to analyze proteins and metallodrug-
protein adducts directly on fresh tissue samples (mass spectrometry imaging) 
[113,114], for a better understanding of the in vivo drug distribution and drug-
biomolecule interactions. 
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2. OUTLINE AND AIMS OF THE RESEARCH PROJECT 
 
 
2.1 Research background 
 
The study of the interaction between anticancer metallodrugs (or novel, promising 
metal compounds) and biomolecules (DNA, proteins) has been the object of 
investigation for many years in our laboratories, with the purpose to contribute to a 
deeper understanding of such interactions and to provide the basis for a rational design 
of new metallodrugs, less toxic and more selective for cancer therapy. In particular, 
valuable structural and functional information on the adducts formed among proteins 
and anticancer metallodrugs/metal compounds were mainly obtained through XRD and 
MS experiments.  
XRD studies involved the use of Pt(II)-, Au(I)-, Au(III)-compounds and proteins of 
very different MW, ranging from the small, model proteins Cyt c, RNase A, Hewl, 
SOD, to the bigger, transport serum proteins Ft and HSA [1-11]. A complete 
description of the results obtained in these experiments is beyond the scope of this 
paragraph and it will be selectively and comparatively faced out in chapter 6. 
In the past years, a wide variety of MS studies were carried out in our laboratories on 
metallated protein adducts and a representative selection is listed below. 
The most investigated metallodrugs included: Pt(II)-compounds, as cisplatin, 
carboplatin and oxaliplatin [12,13]; Ru(III)- and Ru(II)-compounds, as, respectively, 
NAMI-A [14] and RAPTA family [15]; Au(I) complexes, as Auranofin [16]. Often, 
these metallodrugs were studied in comparison with their new and promising 
analogues. Thus, cisplatin and carboplatin analogues, as well as novel promising 
Ru(II), Au(I) and Au(III) compounds, were investigated: Pt(II) iminoethers [17]; Pt(II) 
complexes were ammonia ligands were replaced by the bidentate ethylenediamine 
ligand [13]; diiodidediamine platinum(II) complexes [18,19]; Pt(II) compounds 
bearing sulfur, phosphorus or oxygen mono/bidentate ligands [20-22]; the trans-
(dimethylamino)(methylamino)dichloridoplatinum(II) complex [23]; the Ru(II) 
complex fac-[Ru(CO)3Cl2(N1-1,3-thiazole)] [24]; two analogues of RAPTA 
compounds [25]; Au(I)/Au(III) complexes bearing saccharinate ligands [26]; 
mononuclear Au(III) and dinuclear oxo-bridged Au(III) derivatives both bearing 
heteroaromatic ligands [27-29].  
At variance with XRD experiments reported in references 1-11, the proteins we used in 
the above mentioned MS studies were mainly model proteins: Ub, Cyt c, RNase A, 
Hewl, SOD monomer. These proteins are of moderate to small size, with MW ranging 
from 8 to 16 kDa; they are all commercially available and relatively cheap, water 
soluble and manifest a high stability in solution under physiological-like conditions. In 
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addition, these proteins are easily detectable by MS in positive ion mode. An essential 
step in this research area is in fact represented by the firm characterization and 
modelization of the interactions taking place between representative metallodrugs and 
protein side-chains. It is reasonable to assume that, in spite of the intrinsic structural 
diversity of the various proteins, some common patterns may hold in metal-protein 
interactions related to the specific nature of the metal center and of protein side-chains. 
To this purpose, studies of simple model proteins have turned out to be valuable since 
the choice of relatively simple systems reduces the variables to be taken into account 
and focuses on analogies and differences between the various compounds in the 
presence of different proteins. 
It is not the intent of this paragraph to list all the specific results obtained in the above 
mentioned MS experiments but, rather, to point out the general information that could 
be obtained from the study of this kind of simplified systems: not only the exact 
binding stoichiometry was detected but, thanks to the use of the Orbitrap analyzer, the 
nature of the metallo fragment bound to the protein was unambiguously revealed (see, 
as exemplificative case, reference [30]). 
When the biomolecule’s size increases, as in the case of systems constituted by real 
target proteins, the achievement of a such deep level of molecular information becomes 
more and more difficult. Some experiments, performed in our laboratories with the 
MALDI-TOF and ESI-LTQ-Orbitrap mass spectrometers, confirmed this limit. In 
particular, a MALDI-TOF analysis conducted on the cytosolic TrxR1 enzyme (MW  
55 kDa per monomer) incubated with different gold compounds was only able to 
suggest, due to the inadequate instrumental resolution at those MW, the binding of an 
imprecise number of gold-containing fragments (5-10 equivalents) [31]. Thus, in order 
to gain further insight on the occurring gold-enzyme interactions, and identify those 
residues that undergo metallation, a tryptic digestion of the adducts was performed. 
Moreover, some attempts were made with medium to large size protein metal adducts 
analyzed in the ESI-Orbitrap mass spectrometer: disappointing results were obtained 
since this high resolution mass analyzer explicates its optimal performances with 
maximum molecular weights of about 20-30 kDa. 
The solution to this problem can be found by using different MS analyzers endowed 
with higher resolving powers as, for example, the Q-TOF or better the FT-ICR. 
Alternatively, the above mentioned enzymatic digestion strategy can be exploited. This 
latter approach, besides providing information about the nature of the metallo 
fragments and the binding stoichiometry, is mainly used to reveal the metal binding 
site location on protein, as shown by us in the case of the carboplatin/Cyt c and cis-
diphosphane platinum(II) dichlorides/Cyt c systems: a limited proteolysis with AspN 
enzyme (due to the Cyt c sequence, only two fragments were generated) was 
performed in order to elucidate the binding site position of platinum on that protein 
[13,22].  
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Finally, we have to say that, excluding these three shy approaches attempted on TrxR1 
and Cyt c, our research group have never faced out yet the topic of metallodrug binding 
site location on proteins in a general and systematic way. 
 
 
2.2 Aims of the research project 
 
Within this frame, the aim of this research project was the widening of the knowledge 
related to the characterization, at molecular level, of the adducts formed between 
various kind of metallodrugs (or novel, promising metal compounds) and a number of 
proteins, by using mass spectrometry.  
This aim was pursued through two main search directions: 
i) the study on the chemical nature and the binding stoichiometry of the adducts formed 
between small size proteins and: a) new analogues of cisplatin and oxaliplatin 
anticancer drugs (chapter 3); b) novel Au(III) complexes (chapter 4); 
ii) the development and introduction in our laboratories of an efficient and generally 
applicable method for metallodrugs binding site location on proteins, regardless of the 
MW and nature of the protein and the type of metal complex under investigation, in 
order to get closer to the study of real, interesting biological systems (chapters 5 and 
6). 
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3. DIRECT INFUSION ESI-ORBITRAP ANALYSES TO STUDY 
THE INTERACTION OF MODEL PROTEINS WITH CISPLATIN 
AND OXALIPLATIN ANALOGUES 
 
 
The results presented in this chapter have been published in the following two papers: 
- “Cisplatin and its dibromido analogues: a comparison of chemical and biological 
profiles”. T. Marzo, G. Bartoli, C. Gabbiani, G. Pescitelli, M. Severi, S. Pillozzi, E. 
Michelucci, B. Fiorini, A. Arcangeli, A. G. Quiroga, L. Messori, Biometals, 2016, 29, 
535-542. 
- “PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer 
treatment: chemical and biological features”. D. Cirri, S. Pillozzi, C. Gabbiani, J. 
Tricomi, G. Bartoli, M. Stefanini, E. Michelucci, A. Arcangeli, L. Messori, T. Marzo, 
Dalton Trans., 2017, 46, 3311-3317. 
 
 
3.1. Introduction 
 
Cisplatin is a leading and established anticancer compound in widespread clinical use. 
It is very effective against a few cancer types, such as testicular and ovarian cancer, 
but, despite its clinical success, there are several disadvantages associated with this 
metallodrug, including low water solubility [1], significant toxicity, which limits 
patient doses [1], severe side effects such nausea, nephrotoxicity, neurotoxicity [2] and 
intrinsic or acquired resistance in some cancer types [3,4]. Moreover, cisplatin is 
scarcely active against other important and more frequent solid tumors, like colorectal, 
ovarian and lung cancer [5-7].  
In particular, CRC is today the fourth most common cause of death due to cancer 
worldwide. Adjuvant chemotherapy for CRC mainly relies on fluoropyrimidine 
compounds combined with oxaliplatin. Oxaliplatin (Eloxatin™) is a third-generation 
platinum compound approved by United States FDA in 2002 for the treatment of 
advanced colorectal cancer. Despite its success, frequent intrinsic or acquired 
pharmacological resistance [8], as well as important side effects, such as acute and 
chronic neurotoxicity [9], are still limiting factors to its clinical use.  
With the aim to overcome the main drawbacks of cisplatin and oxaliplatin, in the last 
few decades many analogues of these clinically established metallodrugs have been 
synthesized and tested. 
While thousands of analogues of cisplatin have been prepared and tested so far, quite 
surprisingly the immediate parent platinum compounds that are obtained through 
simple replacement of the two chlorides with different halides as metal ligands (in 
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particular the diiodide and dibromide derivatives) were poorly investigated. Most 
likely, this situation arises from the early misconception and/or generalization that 
chloride replacement with other halides may result into substantial loss of the 
anticancer activity for cisplatin [10-12]. These arguments led us to explore this kind of 
modification in a more systematic way and analyze its chemical and biological 
consequences.  
Recently, we demonstrated that the diiodide analogue of cisplatin manifests truly 
interesting biological properties and warrants a more extensive pharmacological 
evaluation [13]. This encouraging result prompted us to synthetize even the dibromide 
analogue of cisplatin (cisPtBr2; fig. 3.1).  
Similarly, we have prepared the oxaliplatin analogue where the bidentate oxalate 
ligand was replaced by two iodide ligands (PtI2(DACH); fig. 3.1). Notably, this 
oxaliplatin derivative was reported and structurally characterized in 2011 by R. Pažout 
and coworkers [14], but no biological studies were then attempted. The reason that 
makes PtI2(DACH) of particular interest for inorganic medicinal chemists is essentially 
twofold.  
(i) We believe that the replacement of the bidentate oxalate ligand with two iodides 
may affect mainly the activation process of the Pt center, both kinetically and 
thermodynamically, influencing accordingly its overall biological profile. 
(ii) In addition, insertion of two iodide ligands in the place of oxalate is expected to 
increase considerably the lipophilic character of the resulting drug, hopefully 
enhancing cellular uptake and bioavailability. 
 
 
3.2 Materials and MS method 
 
The dibromide analogue of cisplatin and the diiodide analogue of oxaliplatin were 
synthesized in accordance with the procedure described in the two published papers 
reported at pg. 35. 
The selected model proteins for this study were Hewl and RNase A (fig. 3.2). Hewl has 
an average MW of 14305.1 Da (129 amino acids) in its oxidized form and is a 
particularly suitable protein for ESI-MS investigation, as already explained in 
paragraph 2.1. Moreover, this protein is well-known among crystallographers as a 
protein very prone to crystallization, thus turning out very appropriate for possible 
XRD comparative studies of its metallodrug adducts. Similar features can be ascribed 
to RNase A, a protein with an average MW of 13682.2 Da (124 amino acids) in its 
oxidized form. 
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Fig 3.1 Chemical formulae of cisplatin and its dibromide analogue (cisPtBr2), and 
oxaliplatin and its diiodide analogue (PtI2(DACH)). 
 
 
 
Fig. 3.2 Crystal structures of Hewl (PDB 4LZT) and RNase A (PDB 1FS3). 
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The metal complex-protein adduct formation was accomplished by incubating the 
proteins with a three times molar excess of the selected metal compound at different 
incubation times at 37 °C in 20 mM ammonium acetate buffer (pH 6.8). 
The incubated samples did not require purification or separation steps: a simple 
dilution with water was performed before direct infusion of the adduct solution in ESI-
Orbitrap mass spectrometer. Mass spectrometry ionization process is usually sensitive 
to the presence of buffers/salts in the samples but, in this case, buffer removing was not 
necessary thanks to the choice of an MS compatible one. Moreover, adducts were not 
purified from metal complex excess since our previous experience (not reported here) 
and a specific study conducted on this topic (see paragraph 5.3.4), have demonstrated 
that it does not promote false positive adduct formation in ESI source and Orbitrap 
mass spectrometer. Finally, our methodological approach is fast and robust not only 
during sample preparation, but also in terms of instrumental analysis: even in the 
absence of a chromatographic separation among the various adducts formed, very clear 
and informative mass spectra were acquired thanks to the Orbitrap high resolution 
mass analyzer. 
We have also to underline that sample acidification (an usual step in MS protein 
analysis) was not mandatory for the MS analysis of this kind of metal-protein adducts: 
the choice of suitable and well MS-responsive model proteins allowed us to avoid acid 
addition to the samples, thus preventing the possible metallo fragment-protein bond 
impairment (see paragraph 5.3.1)  
For more details on “Materials and methods” see the two published papers reported at 
pg. 35. 
 
 
3.3 Results and discussion 
 
A detailed discussion of all the results obtained in the two published papers reported at 
pg. 35 is not the aim of this chapter. Instead, we want to focus our attention on the 
information obtained through the ESI-MS experiments (the chemical nature and the 
binding stoichiometry of the metal-protein adduct formed, as declared in paragraph 
″2.2 Aims of the research project″) in relationship with those acquired with the other 
investigation techniques used in these two articles. 
When tested in ESI-MS with the Hewl model protein, cisPtBr2 showed a Pt 
coordination that involves the preferential detachment of halide ligands and the full 
retention of ammonia ligands (fig. 3.3).  
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Fig. 3.3 Deconvoluted ESI-Orbitrap mass spectrum of Hewl incubated with cisPtBr2 
(metal:protein ratio = 3:1) recorded after 72 h incubation at 37 °C in 20 mM AA buffer 
at pH 6.8. 
 
This kind of protein metalation strictly resembles that produced by cisplatin, this latter 
resulting in an adduct characterized by selective Pt coordination to His15 following the 
release of the two chloride ligands [15]. Analogously, the study of the in-solution 
behavior (spectrophotometric investigation) and the interaction with calf thymus DNA 
(examined by circular dichroism) showed similarities among the two compounds. 
Cellular studies demonstrated generally comparable cytotoxic effects and the slightly 
greater effects of cisPtBr2 on FLG 29.1 cell line (human acute myeloid leukaemia) may 
be, at least partially, ascribed to its higher lipophilicity compared to cisplatin, which 
could ensue into an increased cellular uptake. Also, even the possible small differences 
in the kinetic of halides release may be invoked to play some role in the slight but 
meaningful differences in the pharmacological effect between cisplatin and its 
dibromide analogue.  
Regarding PtI2(DACH), a survey was conducted in order to study it in comparison to 
oxaliplatin. PtI2(DACH) was incubated with Hewl and RNase A and, in both cases, no 
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metallodrug–protein adduct was detected in ESI-MS, indicating that PtI2(DACH), in 
contrast to oxaliplatin [16,17], is not able to bind these model proteins. An explanation 
for this unexpected behaviour is not straightforward. We previously reported [16,17] 
that coordination of oxaliplatin to Hewl and RNase A could imply a multi-step reaction 
at the level of aspartate residues. First, non-covalent coordination of oxaliplatin to the 
protein occurs; then detachment of one oxygen atom of oxalate from Pt coordination (a 
ring-opening step leading to monodentate oxalate) is observed with concomitant Pt 
coordination of the carboxylate group from an aspartate residue. Finally, the oxalate 
ligand is fully released. We might hypothesize that this multi-step mechanism is 
inhibited when the oxalate ligand is replaced by two iodides due to the lack of 
“recognition” of intact PtI2(DACH) by these model proteins. This hypothesis is 
supported by the results coming from the solution behavior studies that indicated a 
faster release of the two iodide ligands of PtI2(DACH) in comparison with the oxalate 
in oxaliplatin. 
ESI-MS studies in negative ion mode were also performed to analyze the interactions 
between oxaliplatin, or PtI2(DACH), and standard DNA oligonucleotides. In analogy 
with its parent drug oxaliplatin [18], PtI2(DACH) interacts extensively with a standard 
oligonucleotide bearing the GG motif (ODN2, average MW = 3596.4 Da) through a 
classical reaction pattern involving preferential release of iodide ligands (fig. 3.4). 
Regardless of the differences and analogies of behavior highlighted by ESI-MS 
experiments, oxaliplatin and PtI2(DACH) induced roughly comparable cytotoxicity in 
three representative CRC cell lines. This implies that the replacement of oxalate with 
two iodide does not impair the cellular effects of oxaliplatin, that may be thus 
attributed mainly to the [Pt(DACH)]2+ chemical moiety. 
Finally, we strongly believe that the information obtained in this chapter through ESI-
MS experiments are similar to the single tiles of an immense puzzle that, together with 
the information derived from other analytical techniques, provide a better picture of the 
mechanism of action, at the molecular level, for Pt-metallodrugs. 
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Fig. 3.4 Deconvoluted ESI-Orbitrap mass spectrum of PtI2(DACH) incubated with 
ODN2 in water for 72 h at 37 °C; metal to oligonucleotide ratio 1:1.  
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4. DIRECT INFUSION ESI-ORBITRAP AND MALDI-TOF 
ANALYSES TO STUDY THE INTERACTION OF MODEL 
PROTEINS WITH GOLD(III) COMPLEXES 
 
 
The results presented in this chapter have been published in the following three papers: 
- “Gold (III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: 
synthesis, cytotoxicity, DNA and protein binding studies”. C. Martín-Santos, E. 
Michelucci, T. Marzo, L. Messori, P. Szumlas, P. J. Bednarski, R. Mas-Ballesté, C. 
Navarro-Ranninger, S. Cabrera, J. Alemán, J. Inorg. Biochem, 2015, 153, 339-345. 
- “Organogold(III) compounds as experimental anticancer agents: chemical and 
biological profiles”. L. Massai, D. Cirri, E. Michelucci, G. Bartoli, A. Guerri, M. A. 
Cinellu, F. Cocco, C. Gabbiani, L. Messori, Biometals, 2016, 29, 863-872. 
- “Interactions of the organogold(III) compound Aubipyc with the copper chaperone 
Atox1: a joint mass spectrometry and circular dichroism investigation”. T. Marzo, F. 
Scaletti, E. Michelucci, C. Gabbiani, G. Pescitelli, L. Messori, L. Massai, Biometals, 
2015, 28, 1079-1085. 
 
 
4.1 Introduction 
 
Among non-platinum anticancer drugs, in recent years gold(I) and gold(III) complexes 
have attracted much attention because of their strong cytotoxicity in vitro and their 
different mode of action in comparison to cisplatin [1–12]. Indeed, although 
platinum(II) and gold(III) complexes are isoelectronic (d8 configuration) and 
isostructural (square planar geometry), they were found to show different biological 
profiles and mechanisms of action [13]. As already reported in chapter 1, DNA is 
commonly believed to be the primary target for platinum(II) complexes, while 
inhibition of a few crucial proteins seems to be the main mechanism of action for 
cytotoxic gold complexes. In addition, ligand exchange is faster in gold(III) complexes 
compared to platinum(II) ones. In this sense, the chelation of the metallic center with 
multidentate ligands turned out to enhance the stability of the complex, but an 
excessive stabilization of the gold center may be detrimental to the biological activity 
(e.g., Au(cyclam)) [14]. The selection of ligands is also crucial to modulate the 
oxidizing character of the gold(III) center and decrease its pronounced tendency to be 
reduced to gold(I). 
Chelating nitrogen donors, such as phen, bipy, terpy and en, were proposed to control 
these two features [15,16]. Moreover, the presence of a direct C–Au bond further 
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stabilizes the gold(III) center against reduction, as in the case of Aubipyc (1) [16]. 
Examples of Au(III) complexes bearing these chelating ligands are reported in fig. 4.1. 
 
 
Fig 4.1 Chemical formulae of representative Au(III) complexes bearing chelating 
nitrogen donors. 
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We decided to focus our attention on Aubipyc, that is stable under pseudo-
physiological conditions but sufficiently cytotoxic towards different ovarian cancer cell 
lines either sensitive and resistant to cisplatin [17]. In previous studies we tested the 
compound against a panel of 12 cancer cell lines and it was found to produce moderate 
antiproliferative effects [18]. Further studies on the interaction of Aubipyc with model 
proteins revealed that small amounts of metal–protein adducts are formed with Cyt c 
and Hewl; notably, in these adducts the gold(III) center and the C,N,N pincer ligand 
are conserved [19].  
Recently, Aubipyc was reported to form stable adducts, containing gold in the 
oxidation state +1, with the metallochaperone Atox1 protein, as evidenced by 
electrospray ionization high-resolution mass spectrometry [20]. 
Having said this, we decided to elucidate, in deeper detail, the nature of the gold 
binding site in the Aubipyc-Atox1 adduct by MS analyses based on tryptic digestion 
and metal competition experiments. Moreover, we extended our investigations to a 
comparative study involving Aubipyc and its dimer Au2bipyc, on one hand, and the new 
compound Aubipyaa, on the other (fig. 4.2). 
 
Fig 4.2 Chemical formulae of Au2bipyc (2) and Aubipyaa (3). 
 
Finally, our interest was attracted by new gold(III) complexes containing quinoline (4), 
aminoquinoline (5) and hydroxyquinolines (6a, 6b) as ligands (fig 4.3). This interest 
originated from the fact that, in the context of polyaromatic ligands, hydroxyquinolines 
are reported to be promising therapeutic agents for Alzheimer's dementia [21–24] and 
are known to exhibit a variety of biological activities [25–29]. Regarding the 
anticancer activity of the hydroxyquinolines, a number of interesting features were 
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copper ions [30–33]; they induce apoptosis in human cancer cell lines by targeting zinc 
to lysosomes [34]; they are NF-kappa β inhibitors [35,36], or stimulate macrophages to 
release tumor necrosis factor alpha [37], among other anticancer activities. All these 
applications are related to the use of hydroxyquinolines as scavengers of metals 
involved in the pathogenesis of various diseases. Recently, new platinum complexes 
containing hydroxyquinolines in their structure were synthesized and their in vitro 
antitumor activity and interactions with DNA were demonstrated [38]. Therefore, we 
considered worthy of interest the synthesis of new gold(III) complexes analogous to 
these platinum ones in order to study their chemical and biological profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.3 Gold(III) complexes containing quinoline (4), aminoquinoline (5) and 
hydroxyquinolines (6a and 6b) as ligands. 
 
 
4.2 Materials and MS methods 
 
The gold(III) complexes 1-6 were synthesized and characterized as described in the 
three published papers reported at pg. 43. 
The selected model proteins for MS studies were not only the already mentioned (see 
paragraph 3.2) Hewl and RNase A, but also the Cyt c and the Atox1 (fig. 4.4).  
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Fig. 4.4 Crystal structures of Cyt c (RCSB PDB 1HRC) and Atox1 (RCSB PDB 
5F0W). 
  
Cyt c has an average MW of 12360.1 Da (104 amino acids) and is a particularly 
suitable protein for ESI-MS investigation, as already explain in paragraph 2.1. 
Moreover, it has been shown to play a role in apoptosis of cancer cells [39] and so 
could represent a protein target for anti-cancer metallodrugs.  
Atox1, an intracellular metallochaperone protein with an average MW of 7401.6 Da 
(68 amino acids), was cloned from human cDNA expressed in E. Coli. This protein is 
crucially involved in copper trafficking and contains the CXXC motif for copper(I) 
binding in the vicinity of the N-terminus: the Cu(I) center is bound to the two cysteines 
Cys12 and Cys15. The CXXC motif is well prone to accommodate, beyond copper, a 
variety of ‘‘soft’’ metal ions and metallodrugs. Accordingly, it was suggested and 
experimentally proved that the copper trafficking system may play a key role in the 
cellular uptake and processing of platinum-based anticancer drugs with relevant 
pharmacological consequences, making thus Atox1 something more than a simple 
model protein for MS studies with metallodrugs. A few studies documented that 
cisplatin reacts with Atox1 forming stable derivatives [40-43]. Structures of cisplatin 
derivatives of Atox1 were then solved through X-ray diffraction [44] or NMR 
measurements [45], showing a direct interaction of the platinum(II) center with the 
CXXC motif. In turn, a study by Pernilla Wittung-Stafshede et al. investigated the 
reaction of cisplatin with Atox1 through a variety of biophysical methods and 
demonstrated that copper(I) and platinum(II) ions may bind simultaneously to this 
protein to nearby, yet independent and not mutually exclusive, anchoring sites [46,47]. 
Finally, we have recently demonstrated tight binding to Atox1 of a variety of gold 
compounds of medicinal interest, among them being Aubipyc [20].  
Atox1 Cyt c 
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The metal complex-protein adduct formation was performed as already described in 
paragraph 3.2, except in the case of Atox1-metal compound incubations, where rt and 
protein to metal ratios 1:1 or 1:5 were used; a particular attention was paid in order to 
preserve Cys12 and Cys15 in their reduced form (addition of the reducing agent 
dithiothreitol (DTT) and presence of N2 inert atmosphere to avoid O2 effects). 
As already discussed in the case of Pt compounds (see paragraph 3.2), the incubated 
samples did not require any purification, acidification or separation steps before ESI-
Orbitrap analysis. Only in the case of Atox1 and Atox1 adducts, the samples were 
diluted with 1% HCOOH, instead of water, before MS analysis, in order to improve 
their ESI detection in positive ion mode. In fact, while the other proteins used so far 
have a basic pI (over 9.5), human Atox1 has a pI = 6.71. 
The digestion of Atox1 and Atox1-Aubipyc adducts was performed on immobilized 
trypsin tips. This kind of tryptic digestion is faster than the classic in solution one, thus 
limiting the possible oxidation of the derivatives due to the long time of exposure to 
the air. 
The resulting digested peptide mixtures were spotted on an AnchorChip MALDI target 
together with the matrix solution. The dried spots were analyzed with a MALDI-TOF 
spectrometer in order to identify the protein portion containing the gold binding site. 
For more details on “Materials and methods” see the three published papers reported at 
pg. 43. 
 
 
4.3 Results and discussion 
 
As already said in paragraph 3.3, a detailed discussion of all the results obtained in the 
three published papers reported at pg. 43 is not the aim of this chapter. Instead, we 
desire to focus our attention on the information obtained through the ESI-Orbitrap and 
MALDI-TOF experiments and we want to highlight their correlation with the results 
obtained with the other investigation techniques used in these three papers. 
 
The antiproliferative activity of complexes 4, 5, 6a and 6b was investigated on four 
distinct human solid tumor cell lines resulting that three out of four tested gold(III) 
compounds are more active than cisplatin, namely 5, 6a and 6b. DNA electrophoresis 
experiments demonstrated that the interactions of these gold(III) complexes with DNA 
are generally weak and, for this reason, the interactions of 5, 6a and 6b with Cyt c was 
studied. These three compounds showed a remarkable reactivity with this model 
protein with formation of various kinds of adducts (figs. 4.5 and 4.6).  
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Fig. 4.5 Deconvoluted ESI-Orbitrap mass spectra of Cyt c treated with gold 
compounds (a) 6a and (b) 6b after 24 h incubation at 37 °C. 
Chapter 4 
50 
 
 
Fig. 4.6 Deconvoluted ESI-Orbitrap mass spectrum of Cyt c treated with gold 
compound 5 after 24 h incubation at 37 °C (n = 1 or 3). 
 
The most reactive complex toward Cyt c was 6a. Both 6a and 6b reacted with the 
protein just through coordination of the naked Au+ cation with loss of the ligands. 
Multimetallated adducts were detected for all complexes (see peaks Au+ (12554.3 Da), 
2 Au+ (12750.2 Da), 3 Au+ (12946.2 Da) or 4 Au+ (13143.1 Da)). Interestingly, at 
variance with complexes 6a and 6b, for complex 5 it was also possible to detect 
binding to Cyt c with ligand retention (8-aminoquinoline = C9H8N2). Taking into 
account the peak at 12696.3 Da in fig. 4.6, and comparing its experimental 
multicharged isotopic profile (charge state = 7) in fig. 4.7 (a) with the theoretical 
simulation in fig. 4.7 (b), we can assess that in this case the binding seems to be 
occurring through simultaneous coordination of both Au3+ and Au+ ions bound to 
aminoquinoline ligand: the concordance between the two isotopic profiles, as well as 
the low mass difference (- 3.2 ppm) calculated on the higher peaks of the isotopic 
profiles, strongly support this hypothesis.  
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Fig. 4.7 Comparison between (a) the experimental multicharged isotopic profile (z = 7) 
of peak at 12696.3 Da in fig. 4.6 and (b) the theoretical simulation (z = 7) of Cyt c 
bound to a mixture of [C9H8N2Au1]3+ and [C9H8N2Au1]+ in a 1:1 ratio. 
 
For compound 5 is thus conceivable a binding process that first implies the Au3+ 
coordination with 8-aminoquinoline bidentate ligand conservation, followed by Au3+ 
reduction to Au+ with loss of ligand. 
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All these results suggest that the cellular effects produced by these gold compounds 
may be predominantly mediated by interaction with relevant protein targets. 
 
A comparative study involving Aubipyc (1), its dimer Au2bipyc (2) and the novel 
complex Aubipyaa (3) was carried out. The three compounds manifested rather similar 
chemical and biological properties and different grades of reaction with the model 
proteins Cyt c, RNase and Hewl. As demonstrated in a previous paper [19], Aubipyc 
binds both Cyt c and Hewl; at variance, Aubipyaa shows here the formation of an 
adduct only with lysozyme. Furthermore, Aubipyaa seems to exhibit slightly lesser 
affinity with Hewl than Aubipyc. Au2bipyc, unlike Aubipyc and Aubipyaa, besides 
binding Hewl, is able to form an adduct with the RNase A. Notably, regardless the 
different reactivity of the three compounds toward the model proteins, the nature of the 
metallo fragment is always the same, corresponding to the [Au(bipydmb-H)]2+ moiety, 
i.e. the gold(III) center plus the N,N,C terdentate ligand, as proved by ESI–MS analysis 
(figs. 4.8, 4.9 and 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 Deconvoluted ESI-Orbitrap mass spectrum of the mixture Aubipyaa-Hewl 
(gold compound:protein ratio 3:1, 48 h incubation at 37 °C in 20 mM AA buffer, pH 
6.8). 
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Fig. 4.9 Deconvoluted ESI-Orbitrap mass spectrum of the mixture Au2bipyc-Hewl 
(gold compound:protein ratio 3:1, 48 h incubation at 37 °C in 20 mM AA buffer, pH 
6.8). 
Fig. 4.10 Deconvoluted ESI-Orbitrap mass spectrum of the mixture Au2bipyc-RNase A 
(gold compound:protein ratio 3:1, 48 h of incubation at 37 °C in 20 mM AA buffer, pH 
6.8). 
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Finally, we elucidated the nature of the gold binding site in the Aubipyc-Atox1 adduct 
by tryptic digestion/MALDI-TOF analysis and metal competition experiments carried 
out with the ESI-Orbitrap mass spectrometer.  
Under the solution conditions used to monitor metal binding to Atox1, i.e. within the 
strongly reducing environment created by the addition of DTT, the gold(III) center of 
Aubipyc is reduced to gold(I), the terdentate ligand is released and the resulting gold(I) 
species binds Atox1. The main derivative that is formed corresponds to a single bare 
gold(I) ion bound to Atox1 [20]. Adduct formation is well witnessed by deconvoluted 
ESI-MS spectra showing a clear peak at 7465.6 Da, in agreement with previously 
published work [20]. Based on simple coordination chemistry considerations and 
HSAB concepts, it is straightforward to hypothesize that the binding of the soft gold(I) 
may occur at the same level of the soft copper(I). However, to better ascertain this 
point, tryptic digestion was carried out both on the Atox1/Atox1-M mixture alone (the 
protein starting material was a mixture of Atox1 and Atox1 without the N-terminal 
methionine) and on the same mixture incubated with Aubipyc. Then, MALDI spectra 
were recorded from both tryptic digests. Notably, the most abundant tryptic fragment 
obtained from the first mixture was the 1–20 peptide of Atox1-M (fig. 4.11 (a)). Upon 
comparing this spectrum with the one obtained from tryptic digestion of the second 
mixture (i.e. Atox1/Atox1-M incubated with Aubipyc) we noticed the appearance of a 
relatively intense peak at 2319.8 Da due to the binding of one Au+ to 1–20 peptide of 
the reduced Atox1-M (fig. 4.11 (b)). Further, the absence of a peak at 2317.9 Da 
implies that the oxidized form of peptide 1-20 is unable to coordinate the Au+ ion. This 
result is nicely consistent with the hypothesis that gold binding takes place at Cys12 
and Cys15 in the CXXC motif, as already reported for copper(I) and cisplatin as well 
[44]. 
Subsequently, the metal binding properties of Atox1 toward a group of thiophilic metal 
species were explored by ESI-MS, a particular attention being paid to a few exogenous 
metals of medicinal or toxicological relevance such as antimony, arsenic, bismuth and 
mercury.  
At first, a screening was carried out for each metal under the same experimental 
conditions used for Atox1-Aubipyc system. As the result of this preliminary screening, 
adduct formation was demonstrated for bismuth and mercury, while the other species 
failed to form adducts, at least under the here adopted experimental conditions. 
Deconvoluted ESI-MS spectra, documenting adduct formation in the case of mercury 
and bismuth, are shown in fig. 4.12. 
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Fig. 4.11 MALDI-TOF spectra: (a) 1-20 fragment obtained through the tryptic 
digestion of Atox1-M. (b) [1-20 fragment + Au]+ obtained through the tryptic digestion 
of Atox1-M + Aubipyc (24 h of incubation at rt in 20 mM AA buffer, pH 6.8, 1:1 
complex to protein ratio, DTT and N2 inert atmosphere). 
(a) 
(b) 
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Fig. 4.12 Deconvoluted ESI-Orbitrap mass spectra of mixture Atox1/Atox1-M 
incubated with (a) HgCl2 and (b) Bi(NO3)3 (incubation for 24 h at rt in 20 mM AA 
buffer, pH 6.8, 1:1 metal to protein ratio, DTT and N2 inert atmosphere). 
(a) 
(b) 
Atox1 reduced - M 
Atox1 reduced - M + Hg2+ 
Atox1 reduced + Hg2+ 
Atox1 reduced 
Atox1 reduced - M 
Atox1 reduced Atox1 reduced + Bi3+ 
Atox1 reduced - M + Bi3+ 
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Notably, the peak of the adduct, in the case of mercury, is significantly higher than that 
of the native apoprotein, implying a large binding affinity of mercury for Atox1. For 
both species, i.e. mercury and bismuth ions, the formation of a monometallated 
derivative is evident, this suggesting the existence of a single metal binding site. In the 
case of bismuth, we could ascertain that the abundance of this derivative increases with 
increasing the metal to protein ratio, with no evidence of bismetallated species (see SI 
of the related published paper reported at pg. 43). The structure of a Hg-Atox1 
derivative was previously reported [41] within a comparative crystallographic study 
that identified in the CXXC motif the Hg binding site; in contrast, formation of a tight 
adduct between Atox1 and the tripositive bismuth(III) ion is described here for the first 
time. 
Having documented the strong affinity of the above metal species for Atox1, we 
moved to investigate possible competition among them in protein binding. In principle, 
the observation of a direct competition might support the hypothesis that these metal 
species share the same metal binding site; in addition, initial information may be 
inferred on the relative stabilities of the various metal-protein species. This goal could 
be accomplished straightforwardly through a single experiment where Atox1 was 
challenged simultaneously against bismuth, mercury and gold, presented at 1:1 metal 
to protein ratio, under the same experimental conditions reported above. The resulting 
sample was analyzed through ESI-MS and found to exhibit a single major peak at 
7468.7 Da, corresponding to the Hg-Atox1 derivative (fig 4.13). Remarkably, no 
evidence was obtained for any Bi-Atox1 or Au-Atox1 derivatives. These facts strongly 
suggested that the three tested metal species, namely Hg, Bi and Aubipyc, do compete 
for the same metal binding site or region, which realistically corresponds to the CXXC 
motif. Mercury turns out to be, by far, the strongest agonist for the Atox1 metal 
binding site, completely abolishing the binding of either bismuth or Aubipyc to the 
same site. 
 
The outcomes from MS experiments reported in this paragraph have highlighted the 
ability of this technique to offer valuable elucidations regarding the interaction 
between Au(III) complexes and proteins at molecular level, as declared in paragraph 
″2.2 Aims of the research project″: 
- the results supported the idea that proteins can act as primary target for 
quinoline-Au(III) derivatives 5, 6a and 6b. The use of a high resolution mass 
analyzer provided useful information about the mechanism of binding of this 
class of compounds; 
- it was confirmed that the presence of a C-Au bond in compounds 1, 2 and 3 
stabilizes the gold(III) center against reduction, in comparison with complexes 
5, 6a and 6b; 
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- only the presence of a potent reducing agent, like DTT, can reduce the Au(III) 
center of Aubipyc to Au(I) with a complete ligand detachment; 
- the binding of Aubipyc to the peptide 1-20 of Atox1 (most probably on CXXC 
motif) was proved through tryptic digestion/MALDI-TOF experiments as well 
as metal competition/ESI-MS analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13 Deconvoluted ESI-Orbitrap mass spectrum of competition experiment 
between Au, Hg, Bi incubated with Atox1/Atox1-M mixture (incubation for 24 h at rt 
in 20 mM AA buffer, pH 6.8, 1:1 metal to protein ratio, DTT and N2 inert atmosphere). 
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5. MASS SPECTROMETRY AND METALLOPROTEOMICS: A 
GENERAL PROTOCOL TO ASSESS THE STABILITY OF 
METALLODRUG-PROTEIN ADDUCTS IN BOTTOM-UP MS 
EXPERIMENTS 
 
 
The results presented in this chapter have been published in the following paper: 
- “Mass spectrometry and metallomics: a general protocol to assess stability of 
metallodrug-protein adducts in bottom-up MS experiments”. E. Michelucci, G. 
Pieraccini, G. Moneti, C. Gabbiani, A. Pratesi, L. Messori, Talanta, 2017, 167, 30-38. 
 
 
5.1 Introduction 
 
As already explained in paragraph 1.2, ESI-MS represents a powerful tool to study, at 
the molecular level, the interactions between metal based drugs and proteins in such a 
way to rationally design novel and better anticancer metallodrugs through the so called 
“mechanism oriented” approach. 
Regarding the specific topic of metallodrug-protein binding site location through MS, 
two main strategies can be generally exploited: the so-called top-down and bottom-up 
approaches.  
In the top-down approach the whole metallodrug-protein adduct is directly fragmented 
in the mass spectrometer, avoiding any sample pretreatment and consequently reducing 
the possibility to lose the metallo fragments attached to the protein during those 
manipulations. However, its application generally requires the use of high resolving 
power instruments and is restricted to relatively small proteins, mainly because of the 
high complexity of the tandem mass spectra generated (see paragraph 1.2.3). 
The classical bottom-up approach is preferably used for high molecular weight 
proteins, because it involves sample reduction, alkylation and enzymatic digestion 
prior to LC-ESI-MS/MS analysis (see paragraph 1.2.4). However, despite the general 
good stability of the coordination metallodrug-protein bond, each of these 
preparation/analytical steps might compromise the firmness of the metal adducts. 
Halfway, there is the middle-down approach: it consists in a limited digestion process 
in order to generate a small number of peptide fragments of medium to large size (MW 
= 2000-20000 Da). The obtaining of the desired peptides requires the choose of a 
specific enzyme/digestion agent, in correlation to the protein sequence, or a study of 
the digestion times [1,2]. 
In figure 5.1, top-down, middle-down and bottom-up approaches are schematically 
represented. 
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Fig. 5.1 Schematic representation of top-down, middle-down and bottom-up 
approaches. 
 
As previously stated in paragraph 2.2, one of the aims of this PhD project is the 
development and introduction in our laboratories of an efficient and generally 
applicable MS method for metallodrugs binding site location on proteins, regardless of 
the MW and nature of the protein and the type of metal complex under investigation. It 
is our intention to start these MS studies by using, at least at the beginning, basic 
systems consisting of a single protein and one metallodrug, to extend then to simple 
mixtures of known proteins reacted with a metal complex. Finally, our ultimate goal is 
the analysis of more complex samples, such as metallodrug-treated cell populations 
and/or cell homogenates, a situation that reflects more closely the reality of metallic 
species in the cell world: the simultaneous identification of the unknown proteins and 
the metal binding site, as well as the possible quantitative evaluations on protein 
expression, would fully introduce our studies in the metalloproteomics field. 
In this context, the bottom-up approach seemed to us the most suitable method for our 
aims, due to its wide range of applicability. Although this kind of approach has already 
been applied in studies of metal-protein binding side location, in our opinion the 
preparation/analytical conditions didn’t receive yet an adequate attention, at least not in 
a systematic and exhaustive way, in order to ascertain their suitability to preserve 
metal-protein binding along the whole process. 
For example, Moreno-Gordaliza et al. [3] studied in depth the effect of denaturing 
(urea), reducing (DTT) and alkylating (IAA) reagents in the presence of Tris buffer 
during routine procedure for in solution tryptic digestion of CDDP-insulin adducts. The 
same authors [4] tested the stability of the adducts formed between CDDP and five 
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model proteins along the whole in-gel digestion protocol. In turn, Moraleja et al. [5] 
focused their investigations on the comparison of two reducing agents, DTT and TBP, 
used in the FASP procedure [6] for CDDP-protein adducts. 
In any case, the reagents typically used during the enzymatic digestion are not the only 
triggers of metal-protein coordination bond impairment. Karas et al. [7] reported the 
sensitivity of the coordination bond between Fe-heme and histidine in myoglobin to 
some mass spectrometer instrumental parameters (capillary temperature, 
capillary/skimmer voltage), while Li et al. [8] and Loo [9] described its sensitivity to 
pH, to the presence of organic co-solvents and to collision induced dissociation. Also, 
Will et al. [10] listed the requirements that must be fulfilled by CDDP-protein adducts 
for a subsequent MudPIT-MS/MS analysis (kinetic stability over the range 2.3 < pH < 
8.5, metallo fragment persistence on MS/MS fragments). 
These arguments convinced us to design a general protocol to test, a priori and 
systematically, metallodrug-protein adduct stability under the conditions of the 
FASP/bottom-up mass spectrometry approach, starting from the digestion process, 
passing through the LC step and ending with ESI-MS/MS analysis in a LTQ-Orbitrap 
mass spectrometer.  
 
 
5.2 Materials and MS method 
 
We applied the protocol to two model systems, both containing Cyt c (see paragraph 
4.2). For the first system, the well-known CDDP antitumor drug (see paragraph 1.1.3) 
was chosen while, for the second one, the less investigated RAPTA-C (see paragraph 
1.1.4) was selected (fig. 5.2). 
Fig. 5.2 Structures of the metal complexes used in this study. 
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The denaturation, reduction, alkylation and digestion steps were performed with FASP 
procedure, directly on a centrifugal filter device, in order to shorten the contact time 
between these reagents and the metallo fragment-protein adduct, thus limiting the 
possible side reactions causing metal loss. 
Adduct stability to the different critical conditions was monitored by direct infusion in 
the ESI-mass spectrometer, using the Orbitrap high resolution analyzer for acquisition 
and the low resolution IT analyzer to perform CID experiments.  
For more details on the experimental section see the published paper reported at pg. 61 
 
 
5.3 Results and discussion 
 
5.3.1 Critical issues for metallodrug-protein adduct stability in the FASP/bottom-up 
approach using nanoLC-nanoESI-LTQ-Orbitrap-MS/MS analysis: the “nine-point 
testing protocol” 
The development of a reliable testing protocol was necessary on the basis that nothing 
can be said a priori about the stability of the adducts formed between metallodrugs and 
proteins: in fact, the nature of the metal, of its ligands and the protein micro-
environment are variables that can affect, in a deep and unpredictable way, the 
resistance of the metal protein coordination bond during the bottom-up approach. 
The method we intend to use for future studies of binding site location will imply the 
denaturation, reduction, alkylation, digestion FASP procedure and the nanoLC-
nanoESI-MS/MS analysis, preceded by an on-line purification/concentration step. 
Within these steps we identified nine critical situations, either during the sample 
manipulations or instrumental analysis, as potential sources of metal-protein bond 
impairment. These are: 
1) sample permanence in the Ambic buffer 
2) denaturation with urea 
3) reduction with DTT 
4) alkylation with IAA 
5) sample permanence in the loading mobile phase containing CH3CN and TFA 
6) sample permanence in the elution mobile phase containing CH3CN and HCOOH 
7) nanoESI process 
8) transfer of the adducts along the optics of the MS instrument, in particular the ion 
transfer tube and tube lens in a LTQ-Orbitrap 
9) collision induced dissociation in the ion trap. 
In our opinion, these nine points (we called it the “nine-point testing protocol”) 
constitute a useful and almost complete track (though this protocol is obviously open to 
additions and improvements, according to the chosen instrument and the applied 
sample preparation procedures) to be followed whenever one intends to study the 
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stability of metallo fragment-protein adducts throughout the whole bottom-up process. 
The protocol reveals its utility particularly in the case of less studied, or completely 
new, metal complexes. 
 
5.3.2 Cyt c-CDDP and Cyt c-RAPTA-C adduct stability at denaturation, reduction, 
alkylation steps in Ambic aqueous solution (points 1–4) 
Cyt c-CDDP and Cyt c-RAPTA-C solutions were subjected to purification on 
centrifugal filter device, in order to remove the excess of unreacted metal complex 
before adding urea, DTT and IAA. This step avoids undesired side reactions between 
the free metal complex and these three reagents. The solutions were subsequently 
denatured, reduced, alkylated directly on filter and then purified from urea, DTT, IAA 
by centrifugations and washings with 50 mM Ambic. Finally, the solutions were 
incubated overnight on filter at 37 °C to simulate tryptic digestion. The day after 
Ambic was washed away with H2O and the samples, diluted to the desired 
concentration with H2O, were analyzed by ESI-MS. Cyt c-CDDP adducts resulted 
stable toward Ambic, urea, DTT and IAA (data not shown; see the published paper 
reported at pg. 61). Instead, Cyt c-RAPTA-C adducts turned out to be unstable in the 
same conditions (fig. 5.3 a) and b)): indeed, after treatment with Ambic, urea, DTT and 
IAA, the mono-adducts, Cyt c + [Ru(η6-p-cymene)]2+ at 12592.4 Da and Cyt c + 
[Ru(η6-p-cymene)(pta)]2+ at 12750.4 Da, almost or completely disappeared while Cyt c 
at 12358.4 Da became the most intense peak in the spectrum. A deeper investigation 
was carried out on Cyt c-RAPTA-C adduct stability in Ambic using the same 
procedure described above but leaving out the denaturation, reduction and alkylation 
steps. Interestingly, the results showed adducts disappearance in 50 mM Ambic (fig. 
5.3 c)), thus indicating that the use of this latter buffer poses a stability issue.  
Gibson et al. already reported on the sensitivity of ubiquitin-CDDP adducts to Ambic 
[11] and our outcomes confirmed that an accurate evaluation of this crucial parameter 
must be always taken into account, especially in light of the different results obtained 
for Cyt c-CDDP and Cyt c-RAPTA-C: in fact, the same protein, incubated with 
different metal complexes, gives rise to adducts of diverse stability in 50 mM Ambic. 
Indeed, the different behavior of these Pt- and Ru-adducts in 50 mM Ambic is not easy 
to explain and we believe that this issue needs to be studied in depth with further 
experiments. 
We must also underline that Cyt c-RAPTA-C adduct instability in Ambic does not rule 
out further instability to urea, DTT and IAA reagents but, at this level, we decided to 
investigate no longer this issue. In particular, for DTT, it has been already highlighted 
[4] how the disappearance of metal-protein adducts is probably related to the initial 
amount of the latter in the original sample, to their binding strength and their location 
in the protein.  
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Finally, it should be noted that Cyt c would not need reduction/alkylation since its 
unique two cysteines are covalently involved in heme c binding. Nevertheless, in this 
study we decided to perform these two steps in order to show the use of the “nine-point 
testing protocol” in its entirety. 
 
Fig. 5.3 ESI-Orbitrap deconvoluted mass spectra of Cyt c-RAPTA-C adduct solutions 
after a) 72 h incubation in H2O, b) 72 h incubation in H2O and following treatment, on 
filter, with Ambic, urea, DTT and IAA, c) 72 h incubation in H2O and following 
treatment, on filter, with 50 mM Ambic. 
 
5.3.3 Cyt c-CDDP and Cyt c-RAPTA-C adduct stability in loading and elution mobile 
phases (points 5–6) 
We studied the stability of Cyt c-CDDP and Cyt c-RAPTA-C adducts to an organic co-
solvent (CH3CN) and acidity (0.1% TFA or 0.1% HCOOH) present in the loading and 
eluition mobile phases. To evaluate Cyt c-CDDP and Cyt c-RAPTA-C resistance to 
these conditions, we diluted adduct solutions in CH3CN/H2O 1/1 with 0.1% TFA or 
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0.1% HCOOH and we analyzed the resulting samples as such by ESI-MS after 
different incubation times at rt. The excess of metal compound was not removed from 
solutions before ESI-MS analyses: previously performed experiments (data not 
shown), as well as those reported in paragraph 5.3.4 (point 7 of the testing protocol), 
demonstrated the possibility to skip this purification step without the risk of incurring 
in the formation of nonspecific adducts. This purification step was also omitted during 
point 8 of the testing protocol (paragraph 5.3.5). 
The results (spectra not shown here; see the published paper reported at pg. 61) clearly 
show the stability of Cyt c-CDDP and Cyt c-RAPTA-C adducts in the tested 
conditions.  
Actually, it would be more appropriate to apply the stability tests described in this 
section to metallated peptides instead of protein adducts since, during the bottom-up 
approach, digested metallated peptides do come into contact with the mobile phases. 
However, it would be rather complicated and expensive, respectively, to foresee and 
synthesize all these peptides and therefore, in our opinion, this stability test performed 
on denatured protein adducts turns out to be a good compromise.  
 
5.3.4 Cyt c-CDDP and Cyt c-RAPTA-C adduct stability in nanoESI source (point 7) 
During the ESI process, metal-protein adduct dissociation may occur in the source: the 
mere transfer of the adduct from the solution to the gas phase, as well as the presence 
of an inert gas (nitrogen), can induce the detachment of the metal center [12]. In order 
to verify the stability of Cyt c-CDDP and Cyt c-RAPTA-C adducts during ESI process 
(absence of false negatives), aliquots were withdrawn from the two solutions at 
different incubation times, were diluted/denatured in CH3CN/H2O 1/1 with 0.1% 
HCOOH and then analyzed as such by ESI-MS. The nondestructive nature of the 
conventional ESI source was deduced by following the kinetic of adduct formation. 
The ESI-Orbitrap deconvoluted mass spectra of Cyt c-CDDP adduct solution at 
different incubation times are reported in fig. 5.4: the intensity of the adduct peaks 
grows congruently with time and, mutually, unreacted Cyt c peak intensity decreases.  
Similar results were obtained for the system Cyt c-RAPTA-C (data not shown; see the 
published paper reported at pg. 61). 
By the same experimental evidences, we also deduced the absence of nonspecific bond 
formation (false positives) between Cyt c and CDDP (or RAPTA-C) in conventional 
ESI source, even omitting the removal of the metal compound excess from the 
incubation solution. 
A fortiori, the conservativeness of the nanoESI source, that will be used in our bottom-
up approach, is ensured: nanospray is believed to be more gentle than conventional 
electrospray since lower voltages are applied and there is no presence of additional 
nitrogen (therefore there are fewer activating collisions in the nanospray source [9]). 
As already reported in the previous paragraph, it would be more appropriate to apply 
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this stability test to metallated peptides instead of protein adducts but, for the same 
reasons explained above, its application to denatured protein adducts is a good 
compromise. 
 
 
Fig. 5.4 ESI-Orbitrap deconvoluted mass spectra of Cyt c-CDDP adduct solution at 
different incubation times in 20 mM AA buffer pH 6.8: a) t = 0 h, b) t = 24 h, c) t = 48 
h, d) t = 72 h, e) t = 144 h. 
 
5.3.5 Cyt c-CDDP and Cyt c-RAPTA-C adduct stability to instrumental parameters 
(point 8) 
We studied Cyt c-CDDP and Cyt c-RAPTA-C adduct stability to the variations 
imposed to capillary temperature/voltage applied to the ion transfer tube, and to tube 
lens voltage. The adduct solutions were diluted in CH3CN/H2O 1/1 with 0.1% HCOOH 
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and directly analyzed by ESI-MS. Cyt c-CDDP and Cyt c-RAPTA-C adducts showed 
their complete stability to the variations imposed in the mass spectrometer (spectra not 
shown here; see the published paper reported at pg. 61). 
For the same reasons already explained in the previous two paragraphs, also these 
stability tests were performed on denatured protein adducts instead of metallated 
peptides. 
 
5.3.6 Metallo fragment-peptide adduct stability at CID (point 9) 
Experiments were carried out to evaluate the stability at CID of metallo fragment-
peptide adducts generated during the enzymatic digestion of metallo fragment-protein 
adducts. This test aims to investigate the resistance to CID not only of Pt-peptide (or 
Ru-peptide) bond but also of Pt-ligand (or Ru-ligand) one. In fact, the energy provided 
during MS/MS experiments for peptide chain sequencing could generate, in addition, 
breakage of metal-peptide and metal-ligand bonds. In particular, the study of this last 
type of fragmentation provides important information to be used in the design of 
targeted MS/MS experiments [14] and in the subsequent reworking of bottom-up 
results through search engines [15], like Sequest and Mascot, or by manual 
interpretation [6].  
From an experimental point of view, the above-mentioned stabilities were evaluated by 
using a simplified system consisting of CDDP, or RAPTA-C, incubated with model 
peptides. The choice of the model peptides was done by taking into account the high 
affinity of Pt(II) and Ru(II) complexes for S- and N-donors contained in amino acid 
side chains [16-18]. For our experiment, in order to explain how to deal with point 9) 
of the testing protocol, we selected the model tetrapeptides MRFA, containing Met, 
and EHSG, containing His, leaving out, in the first instance, other possible S-, N- and 
O-donors. Obviously, for a general applicability of such test, the nature of the model 
peptides will have to be modulated, from time to time, depending on the specific nature 
of the metal complex under examination.  
In each of the four incubation mixtures (CDDP-MRFA, CDDP-EHSG, RAPTA-C-
MRFA, RAPTA-C-EHSG), a specific Pt-peptide, or Ru-peptide, adduct ion was 
selected for CID experiments. Figs. 5.5 and 5.6 show the CID spectra of the four 
selected peptides, namely [MRFA+Pt2+-H+]+ at 717.22 m/z, 
[EHSG+Pt(NH3)(DMSO)2+-H+]+ at 717.16 m/z, [MRFA+Ru(η6-p-cymene)2+-H+]+ at 
758.27 m/z and [EHSG+Ru(η6-p-cymene)(pta)2+-H+]+ at 820.25 m/z. In each spectrum 
30% relative collision energy was used, the same that will be imposed for bottom-up 
experiments, and the appropriate isolation width was selected in order to include the 
entire and characteristic isotopic pattern typical of Pt and Ru compounds. CID spectra 
of figs. 5.5 and 5.6 show the stability of metal-amino acid bonds, namely Pt-Met, Pt-
His, Ru-Met and Ru-His, at the energy tested while a partial loss of Pt ligands (NH3 
and DMSO, fig. 5.5 b)) and Ru ligands (pta and η6-p-cymene, fig. 5.6) is observed.  
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Fig. 5.5 ESI-CID mass spectra (fragmentation in IT, acquisition in Orbitrap) of a) 
[MRFA+Pt2+-H+]+ and b) [EHSG+Pt(NH3)(DMSO)2+-H+]+. The formation of peptide-
CDDP (as well as Cyt c-CDDP) adducts containing DMSO as ligand is due to the 
initial solubilization of CDDP in that solvent. 
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Fig. 5.6 ESI-CID mass spectra (fragmentation in IT, acquisition in Orbitrap) of a) 
[MRFA+Ru(η6-p-cymene)2+-H+]+ and b) [EHSG+Ru(η6-p-cymene)(pta)2+-H+]+. 
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The information on Pt metallo fragment stability at CID will turn out useful in the 
bottom-up experiments of chapter 6 (see paragraph 6.2.5).  
It is also interesting to notice the presence of fragments containing Ru4+ (attributions 
verified through simulations not reported here; see the published paper reported at pg. 
61) in the CID spectrum of [MRFA+Ru(η6-p-cymene)2+-H+]+ probably due to some 
rearrangements and/or redox processes during fragmentation in IT. 
 
 
5.4 Conclusions 
 
In this work we have designed a general and systematic protocol to test, a priori, the 
stability of metallodrug-protein adducts under the typical conditions of the 
FASP/bottom-up mass spectrometry approach. This study may turn helpful to scientists 
working in the field of metalloproteomics and investigating metallodrug-protein 
interactions. The protocol here developed constitutes a useful and almost complete 
track to be followed but it is obviously open to additions and improvements, according 
to the chosen MS instrument and the applied sample preparation procedures. The 
protocol was specifically applied to two representative model systems, Cyt c-CDDP 
and Cyt c-RAPTA-C. Cyt c-CDDP adducts were stable in all tested conditions, while 
Cyt c-RAPTA-C adducts manifested a remarkable instability in the 50 mM ammonium 
bicarbonate buffer. This latter finding demonstrates the advisability to perform a test-
protocol like this when starting any bottom-up MS investigation on protein-
metallodrug systems, especially with novel, or scarcely studied, metal complexes. In 
fact, the nature of the metal, of its ligands and of the protein microenvironment are 
variables that may undoubtedly affect the stability of the metal-protein coordination 
bond during the bottom-up approach, and are not easy to predict. 
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6. CISPLATIN BINDING SITE LOCATION ON CYTOCHROME 
C AND HUMAN SERUM ALBUMIN: FASP/BOTTOM-UP MASS 
SPECTROMETRY APPROACH 
 
 
6.1 Introduction 
 
As reported in chapter 2, one of the aims of this PhD thesis was the development and 
introduction in our laboratories of an efficient and generally applicable method for 
metallodrugs binding site location on proteins, regardless of the MW and nature of the 
protein and the type of metal complex under investigation. The preliminary stability 
tests performed in chapter 5 demonstrated the resistance of CDDP-Cyt c adducts to all 
the preparative/analytical steps of the selected FASP/bottom-up nanoLC-nanoESI-
MS/MS approach. Consequently, we decided to perform our first systematic study of 
binding site location on this model system.  
This system has already been intensively investigated in the literature in order to 
elucidate Pt position on Cyt c, but the reported results are not completely concordant 
with each other. Zhao et al. found Met65 as primary binding site of CDDP on Cyt c 
through bottom-up infusion-ESI-LTQ-Orbitrap-MS/MS and MS3 analyses on the 
digested peptide mixture [1], while Zhang et al., with the same kind of experiment 
performed on a FT-ICR mass spectrometer, discovered three more binding sites, 
namely Met80, His18 and His33 [2]. In turn, Gordaliza et al. identified Glu61, Glu62, 
Thr63, Met65 and Met80 as binding sites by a nanoLC-ESI-LTQ-MS/MS gel-based 
bottom-up approach [3]. Finally, Ferraro et al. studied the system with an XRD 
experiment and they found Glu61 and Met65 as Pt binding sites [4]. The partial 
concordance of these results can be certainly attributed to the different 
preparative/analytical conditions used for sample analysis and this issue makes the 
study of CDDP-Cyt c binding site location a topic that still deserves to be investigated. 
Within this frame, the results of our study will benefit, on one hand, from the 
comparison with the ones already present in the literature, in order to ascertain their 
reliability and, on the other hand, they could generate new knowledge on this still 
controversial topic. 
In parallel, we decided to apply the FASP/bottom-up nanoLC-nanoESI-MS/MS 
approach to the investigation of CDDP binding sites on HSA, in order to test the 
method on a more complex system than the CDDP-Cyt c model, thus opening the way 
to studies involving proteins that are actual targets for metallodrugs. 
HSA (fig. 6.1) is the most abundant plasma protein (about 52%). It consists of a single 
chain with 585 amino acids (MW 66-67 kDa) organized in three domains (I, II and III), 
each of which contains two subdomains (IA, IB, etc.). It is basically a helical protein 
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(67% of -helix content) and its amino acid sequence contains 17 disulfide bridges and 
one thiol group (Cys34) which is a potential binding site toward many type of 
compounds, including metallodrugs [5]. 
 
 
Fig. 6.1 Crystal structures of HSA (PDB 4K2C). 
 
HSA, together with other serum proteins, like transferrin, may perform a transport 
function for platinum based-drugs and influence the overall drug distribution and 
excretion, as well as its efficacy, activity and toxicity. Controversial opinions still exist 
on the consequences of cisplatin binding to HSA. Some authors postulate that human 
serum albumin forms a ‘‘reservoir’’ for the biologically active Pt species, while others 
consider Pt binding to serum albumin as a form of drug inactivation. For example, it 
was suggested that an excessive cisplatin affinity for HSA may prevent its effective 
tissue delivery, thus hampering the antitumor actions [6]. On the other hand, it was 
shown that hypoalbuminemic patients respond poorly to cisplatin treatment [7]. 
Additionally, albumin binding may prevent some of the side effects of cisplatin 
treatment, especially its nephrotoxicity [8]. Therefore, an understanding of the 
molecular mechanism of albumin-cisplatin interactions may have an impact on the 
optimization of strategies for cisplatin treatment. 
The CDDP-HSA system has already been studied in the literature; attention has been 
paid to Pt binding site location and, as already reported for the system CDDP-Cyt c, 
also in this case the results are not completely concordant with each other. Gordaliza et 
al. identified His288, Cys289, Met298, Met329 and His338 as binding sites by a 
nanoLC-ESI-LTQ-MS/MS gel-based bottom-up approach [3]. Will et al. found Cys34, 
Tyr148, Tyr150, Met329, Asp375, Glu376 and Met548 through bottom-up 
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multidimensional nanoLC-nanoESI-LTQ-MS/MS analyses [9], while Moraleja et al., 
by bottom-up FASP-OFFGEL/IEF-nanoLC-nanoESI-LTQ-Orbitrap-MS/MS 
experiments, found His9, Asp13, His67, His105, His128, His247, Met298 and Met329 
as binding sites [10]. In turn, Hu et al. found His67, Cys124, His128, His247 and 
Met298 through LC-ESI-Q-TOF-MS/MS bottom-up approach [11]. Finally, Ivanov et 
al., by NMR experiments, found Met87, Met298 and Met446 as CDDP binding sites 
on HSA [6], while Ferraro et al. found His67, His105, His247, His288, Met298, 
Met329, His535 and Met548 through XRD analysis [12]. 
Again, as in the case of CDDP-Cyt c adducts, we will exploit the results already 
present in the literature for the CDDP-HSA adducts in order to verify the reliability of 
the binding sites we will find for this last system. On the other hand, our findings could 
confirm the current knowledge or bring new information to be used for a better 
comprehension of the nature of the binding sites of CDDP on HSA. 
Finally, for the automated search of the binding sites of Pt on proteins, we decided to 
use Mascot search engine, already employed in our laboratories for "classical" 
proteomics experiments. To the best of our knowledge, it is the first time that this 
interface is exploited for metalloproteomics purposes with the aim to locate metal 
binding sites.  
 
 
6.2 Experimental 
 
6.2.1 Solvents, reagents and materials 
Water (412091) and acetonitrile (412042), both UHPLC-MS grade, were purchased 
from Carlo Erba (BP 616, F-27106, Val de Reuil Cedex, France). Ammonium acetate 
(A1542), ammonium bicarbonate (09830), DTT (43815), IAA (57670), HCOOH 
(56302) and TFA (40967) were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and urea from Serva (Heidelberg, Germany). Sequencing grade modified trypsin 
(V5111) was purchased by Promega (Madison, WI, USA). Microcon centrifugal filter 
devices with nominal cutoff of 3 kDa (42404) or 10 kDa (42407) were purchased from 
Millipore (Bedford, MA 01730, USA). CDDP (P-4394), HSA (A-3782) and horse 
heart Cyt c (C7752) were purchased from Sigma-Aldrich.  
 
6.2.2 Cyt c-CDDP and HSA-CDDP adduct formation and purification 
Nine mg of CDDP (final concentration 300 M) were dissolved in 100 ml of 20 mM 
AA buffer at pH 6.8. To 1 ml of this solution, 1.2 mg of Cyt c or 6.6 mg of HSA 
(protein concentration 100 M; protein to metal ratio 1 to 3) were added, respectively. 
The two solutions were incubated for 144 h at 37 °C (the adduct formation was 
monitored by direct infusion in the ESI-Orbitrap for Cyt c and in ESI-IT for HSA, 
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using the conditions and instrumental settings already reported by Michelucci et al. 
[13]). After this time, an aliquot containing 50 μg of protein/protein adducts was 
withdrawn from each solution and purified on the proper centrifugal filter device (3 
kDa for Cyt c and 10 kDa for HSA): dilution on filter with 200 μl of 50 mM Ambic, 
spinning for 45 min at 13,000 rpm, washing with 200 μl 50 mM Ambic and again 
spinning for 45 min at 13,000 rpm. The same procedure of purification was performed 
for the solutions of Cyt c and HSA in AA not incubated with CDDP.  
 
6.2.3 FASP procedure: denaturation, reduction, alkylation and digestion steps 
The four purified samples were denatured on centrifugal filter device (200 μl of 8 M 
urea in 50 mM Ambic were added and the filter was spun for 45 min at 13,000 rpm; 
this procedure was repeated once and then 200 more μl of 8 M urea in 50 mM Ambic 
were added). For the reduction step, 3.3 μl of a freshly prepared 0.5 μg/μl DTT 
aqueous solution (30:1 protein-to-DTT ratio, w/w) were added directly on each 
centrifugal filter device and the samples were incubated for 30 min at room 
temperature (rt). For the alkylation step, 3.3 μl of a freshly prepared 2.5 μg/μl IAA 
aqueous solution (6:1 protein-to-IAA ratio, w/w) were added directly on each 
centrifugal filter device and the samples were incubated for 20 min at rt in the dark. 
The four samples were then purified from urea, DTT and IAA (the samples were spun 
for 30 min at 13,000 rpm, twice washed with 100 μl of 50 mM Ambic and spun for 30 
min at 13,000 rpm). The samples were then diluted with 100 μl of 50 mM Ambic and 
finally overnight digested at 37 °C on filter with trypsin (30:1 protein-to-trypsin ratio, 
w/w). The morning after a new reservoir was placed under each filter and the samples 
were spun for 25 min at 13,000 rpm. The filters were washed with 30 μl of 50 mM 
Ambic and spun for 25 min at 13,000 rpm. These last two steps were repeated twice. 
The four peptide mixtures recovered in the reservoir were subjected to nanoLC-
nanoESI-MS/MS analysis. 
 
6.2.4 NanoLC-nanoESI-MS/MS analysis 
The four peptide mixtures were submitted to nanoLC-nanoESI-MS/MS analysis on an 
Ultimate 3000 HPLC (Dionex-Thermo Fisher, San Donato Milanese, Milano, Italy) 
coupled to a LTQ Orbitrap mass spectrometer (Thermo Fisher, Bremen, Germany). For 
each sample, 5 μl were injected. Peptides were concentrated on a precolumn cartridge 
PepMap100 C18 (300 μm i.d. × 5 mm, 5μm, 100 Å, LC Packings Dionex) and then 
eluted on a homemade nano column packed with Aeris Peptide XB-C18 phase (75 μm 
i.d. × 15 cm, 3.6 μm, 100 Å, Phenomenex, Torrance, CA, USA) at 300 nl/min. The 
loading mobile phases were: 0.1% TFA in H2O (phase A) and 0.1% TFA in CH3CN 
(phase B). The elution mobile phases composition was: H2O 0.1% formic acid/CH3CN 
97/3 (phase A) and CH3CN 0.1% formic acid/ H2O 97/3 (phase B). The elution 
program was: 0 min, 4% B; 10 min, 40% B; 30 min, 65% B; 35 min, 65% B; 36 min, 
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90% B; 40 min, 90% B; 41 min, 4% B; 60 min, 4% B. Mass spectra were acquired in 
positive ion mode, setting the spray voltage at 1.8 kV, the capillary voltage and 
temperature at 45 V and 200 °C, respectively, and the tube lens at 130 V. Data were 
acquired in data-dependent mode with dynamic exclusion enabled (repeat count 2, 
repeat duration 15 s, exclusion duration 30 s); survey MS scans were recorded in the 
Orbitrap analyzer in the mass range 300‐2000 m/z at a 15,000 nominal resolution at m/z 
= 400; then up to three most intense ions in each full MS scan were fragmented 
(isolation width 3 m/z, 30% relative collision energy) and analyzed in the IT analyzer. 
Monocharged ions did not trigger MS/MS experiments. Xcalibur 2.0 software 
(Thermo) was used for data acquisition. 
 
6.2.5 Mascot automated search and subsequent manual check 
The acquired data were searched with Mascot Daemon 2.4.0 search engine (Matrix 
Science Ltd., London, UK) against a customized database consisting of, respectively, 
the horse heart Cyt c (Uniprot P00004) or the HSA (Uniprot P02768) sequence. For 
Mascot search on peptide mixture coming from Cyt c digestion, the following variable 
modifications were introduced: N-terminal acetylation, heme+ group on C and 
oxidation of M. For the peptide mixture coming from Cyt c incubated with CDDP, in 
addition to those above mentioned, other variable modifications were introduced on the 
potentially coordinating residues C, D, E, H, K, M, T, W and Y: [Pt]2+, [(NH3)Pt]2+, 
[(NH3)2Pt]2+ and [(NH3)2PtCl]+. For the peptide mixture coming from HSA digestion 
the introduced variable modifications were: carbamidomethylation and cysteinylation 
on C, oxidation on M, phosphorylation on S, T, Y, and N-glycosylation on R and K. 
Finally, for the peptide mixture coming from the digestion of HSA incubated with 
CDDP, the introduced variable modifications were: carbamidomethylation and 
cysteinylation on C, oxidation on M, N-glycosylation on K, and [Pt]2+, [(NH3)Pt]2+, 
[(NH3)2Pt]2+, [(NH3)2PtCl]+ on the potentially coordinating residues C, D, E, H, K, M, 
S, T, W and Y. The monoisotopic mass values were used for the calculation of the 
mass gains related to the variable modifications. In order to consider the net loss of two 
protons from the bi-charged modifications and of one proton from mono-charged 
modifications, two mass units or one mass unit were subtracted, respectively, from the 
monoisotopic mass of the modification itself. The Mascot searches were performed 
considering: (i) trypsin as enzyme, (ii) up to two missed cleavage sites, (iii) 10 ppm of 
tolerance for the monoisotopic precursor ion and 0.5 mass unit for monoisotopic 
fragment ions, (iv) only bi-, tri- and tetra-charged precursor peptides. Following the 
Mascot automated search, precursor peptide and MS/MS spectra were visually 
assessed to positively confirm the presence of platinum in Mascot assignments on the 
basis of the characteristic isotopic pattern of platinated peptides. Peptide sequences 
whose MS or MS/MS spectra did not respect this criterion were removed from the final 
list of the correct assignments. 
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6.2.6 HSA-CDDP adduct stability at denaturation, reduction, alkylation, digestion in 
Ambic and in loading/elution mobile phases: sample preparation for ICP-AES 
analyses 
One ml of HSA-CDDP adduct solution (protein concentration 100 M, CDDP 
concentration 300 M) was purified from unbound Pt excess and AA with a procedure 
analogue to that already described in paragraph 6.2.2, but using water in the three 
washing steps. The filter was then spun upside down at 3500 rpm for 3 min and the 
volume recovered was diluted to 1 ml with H2O. Twenty-five l of this solution were 
diluted with H2O to the final volume of 500 l (final protein concentration 5 M) and 
directly analyzed by ICP-AES. Moreover, three aliquots (50 l each) were withdrawn 
from the purified solution and were subjected to the stability tests to a) urea, DTT, 
IAA, Ambic, b) loading mobile phase and c) elution mobile phase, according to the 
protocol reported in the published paper by Michelucci et al. (see pg. 61). At the end of 
the stability tests, the three samples were opportunely purified and diluted with H2O to 
the final volume of 1 ml (protein concentration of 5 M). Different volumes of the 
three samples (840 l for sample a) and 800 l for samples b) and c)) were analyzed by 
ICP-AES. 
 
6.2.7 ICP-AES analyses 
The determination of protein bound platinum was performed by a Varian 720-ES 
Inductively Coupled Plasma Atomic Emission Spectrometer equipped with a CETAC 
U5000 AT+ ultrasonic nebulizer, in order to increase the method sensitivity. The four 
samples prepared in paragraph 6.2.6. were put in PE vials and digested in a thermos-
reactor at 90 °C for 24 h with 2 ml of aqua regia (HCl and HNO3, both suprapure 
grade, at 3:1 ratio). After digestion, the samples were diluted to a final volume of 6 ml 
with ultrapure water ( 18 M), were spiked with 1 ppm of Ge, used as the internal 
standard, and analyzed. Calibration standards were prepared by gravimetric serial 
dilution from commercial standard solution of Pt at 1000 mg/L. The wavelength used 
for Pt determination was 214.424 nm whereas for Ge the line at 209.426 nm was used. 
The operating conditions were optimized to obtain maximum signal intensity and, 
between each sample, a rinse solution of aqua regia was use in order to avoid any 
“memory effect”. 
 
 
6.3 Results and discussion 
 
6.3.1 Adduct formation, FASP procedure and nanoLC-nanoESI-MS/MS analyses 
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The adduct formation in CDDP-Cyt c solution was monitored by ESI-Orbitrap 
infusions (see fig. 6.2). 
 
Fig. 6.2 ESI-Orbitrap deconvoluted mass spectrum of Cyt c-CDDP solution after 144 h 
incubation at 37 °C in 20 mM AA, pH 6.8 (1:3 Cyt c:CDDP ratio). 
 
To explain the structure of the adducts reported in fig. 6.2, we supposed that the protein 
acts as a multidentate ligand, as previously reported by Gibson and Costello for the 
CDDP-ubiquitin system [14]. The Pt–N bonds are kinetically inert and 
thermodynamically stable, whereas Pt–Cl bonds are semilabile and Pt–O bonds are 
labile. Pt–S bonds are inert and have a strong trans effect, i.e. they labilize the bonds 
that are trans to the sulfur atom. The course of the reaction between CDDP and Cyt c 
probably involves the initial aquation of one chloride ligand to yield [cis-
Pt(NH3)2Cl(H2O)]+ which reacts with the side chain of an amino acid (probably M) to 
form a monodentate covalent adduct cis-Pt(NH3)2Cl(Cyt c)m (m = monodentate). The 
second chloride ligand is then substituted by an aqua ligand to give the more reactive 
monodentate cis-Pt(NH3)2(H2O)(Cyt c)m. Excluding the loss of a ligand during the 
ionization process [15], we believe that aqua ligand on the bound platinum is 
substituted by a nucleophile on the protein to form the bidentate adduct cis-
Pt(NH3)2(Cyt c)b (b = bidentate). Although platinum(II)–ammine bonds are inert, the 
thioether group of methionine is known to trans-labilize the ammine ligand from 
cisplatin. Trans-labilization of the ammine ligand could lead to the substitution of the 
inert ammine ligand by the reactive water ligand that, in turn, can react with another 
amino acid side chain to form a tridentate adduct, Pt(NH3)(Cyt c)t (t = tridentate) with 
Cyt c + [Pt(NH
3
)]
2+
 
Cyt c 
Cyt c + 2[Pt(NH
3
)]
2+
 
tris-adducts Cyt c + Pt
2+
 
Cyt c + [Pt(NH
3
)
2
]
2+
 
Cyt c + 2[Pt(NH
3
)
2
]
2+
 
Da    
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MW = 12569.3 Da. Theoretically, even tetradentate adducts are possible and, in our 
specific case, they are formed only in small quantity. 
The adduct formation in CDDP-HSA solution was monitored by ESI-IT infusions (see 
fig. 6.3). 
Fig. 6.3 ESI-IT multicharged mass spectrum of HSA-CDDP solution a) before CDDP 
addition and after b) 24 h, c) 48 h, d) 72 h, e) 144 h incubation at 37 °C in 20 mM AA, 
pH 6.8 (1:3 HSA:CDDP ratio). 
 
As already explained in paragraph 2.1, our Orbitrap high resolution mass analyzer is 
able to properly detect molecules with a maximum MW of 20-30 kDa. Since HSA MW 
is about 66-67 kDa, we were forced to use the low resolution analyzer IT to follow its 
platinated adduct formation. This formation is well documented by comparing the ESI-
IT multicharged spectra of HSA solution before (fig. 6.3 a) and after (fig. 6.3 b-e) 
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CDDP addition: the generation of new signals, that decreases peak resolution, and the 
shift of the multicharged profile to higher masses are a clear witness of the binding of 
metallo fragments to HSA.  
In order to obtain a more direct prove of platinated adduct formation, the HSA-CDDP 
solution was, first of all, carefully washed on centrifugal filter device to remove the 
unbound Pt excess and then was subjected to ICP-AES analysis. A Pt to protein molar 
ratio 2.9:1 was determined.   
Before starting with the bottom-up MS approach on HSA-CDDP adducts, we decided 
to investigate on their stability during this procedure. As already reported for the 
system Cyt c-CDDP in paragraph 5.3.4, HSA-CDDP adduct stability in nanoESI 
source can be deduced by following the kinetic of adduct formation shown in fig. 6.3: 
the multicharged profile shifts to higher masses congruently with the increasing of the 
incubation time, thus indicating the non-involvement of the nanoESI process in adduct 
formation/destruction. For the stability tests to urea, DTT, IAA, Ambic and 
loading/elution mobile phases, we followed the protocol cited in the paper reported at 
pg. 61 and we verified the presence of Pt on HSA by ICP-AES analyses. In particular, 
after denaturation, reduction, alkylation and Ambic treatment, a Pt to protein molar 
ratio 2.3:1 was determined, while, after permanence in loading and elution mobile 
phases, 2.7:1 and 2.5:1 Pt to protein molar ratios were, respectively, found. HSA-
CDDP adduct stability to instrumental parameters was verified according to the testing 
protocol reported in chapter 5: the analysis of the acquired spectra (not reported here) 
seemed to confirm the stability to the variations imposed to capillary 
temperature/voltage applied to the ion transfer tube and to tube lens voltage; however, 
these data were not as informative as those reported for the system Cyt c-CDDP, due to 
the low resolution of the ion trap analyzer. Finally, regarding the stability of the 
metallo fragment-peptide adducts at CID, the results obtained for the Cyt c-CDDP 
system (see paragraph 5.3.6) can be extended to the HSA-CDDP one: in fact, the metal 
compound and the amino acids involved in the binding are the same.  
Before starting with the denaturation step, Cyt c, CDDP-Cyt c, HSA and CDDP-HSA 
solutions were put on centrifugal filter device and washed with 50 mM Ambic. The 
washing with ammonium bicarbonate fulfills a dual function: it sets the right pH value 
for the tryptic digestion step and removes the unbound CDDP excess from CDDP-Cyt 
c and CDDP-HSA solutions. The removal of Pt excess from these solutions is 
particularly important in order to avoid undesired side reactions between the free metal 
complex and the reagents used during the subsequent denaturation, reduction, 
alkylation and digestion steps. The FASP procedure was chosen, as already explained 
in chapter 5, to limit the contact time between the denaturing/reducing/alkylating 
agents and the metallo fragment-protein adducts, thus avoiding possible side reactions 
causing metal loss. Moreover, it should be noted that Cyt c would not need reduction-
alkylation steps since its unique two cysteines are covalently involved in heme c 
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binding. Nevertheless, in this model study, we decided to perform these two steps in 
order to practice with the procedure in its entirety. 
The instrumental analysis consisted of an initial on-line purification/concentration step, 
in order to eliminate Ambic from the peptide mixtures before injection into the nano 
column, followed by a nanoLC-nanoESI-MS/MS analysis. The sample quantities we 
had to deal with did not necessarily required the use of nanoflows. However, we 
decided, for these first attempts, to already set the instrument in a configuration proper 
to analyze future samples, potentially available in small quantity or lower 
concentration. 
 
6.3.2 How to “deceive” the Mascot search engine designed for “classical” proteomics 
and force it to work in metalloproteomics 
The files generated by nanoLC-nanoESI-MS/MS analyses were used for an automated 
Mascot search.  
Mascot, together with Sequest (Proteome Discoverer, Thermo) and Andromeda 
(MaxQuant, Max Planck Institut für Biochemie), is one of the most famous search 
engine used in “classical” proteomics experiments. These softwares are not specifically 
designed for metalloproteomics purposes and their application is effectively limited to 
bottom-up analysis of small peptides containing common elements such as C, H, N, O, 
S and P. 
On the other hand, there is an increasing interest in the study of the interaction of 
proteins with heavy elements of biological and medicinal relevance. These include Cr, 
Mo, W, Fe, Ru, Os, Pd, Pt, Cd, Hg, Pb, Se and Gd, all of which feature lightest 
isotope(s) of low abundance(s). Due to this fact, ions containing these isotopes may not 
be easily detected and may present complicated isotopic patterns. 
The employment of the aforementioned search engines for metalloproteomics purposes 
is however possible, but a number of tricks must be used: 
- the most abundant isotope of the metal element is manually defined to be the 
'lightest isotope' (e.g., 190Pt, 192Pt, 194Pt, 195Pt, 196Pt, 198Pt); 
- the software assumes that protons are the only source of positive charges in 
spectra generated by electrospray ionizations, so users need to manually 
subtract proton(s) from ions containing fixed positive charge(s) from other 
elements (e.g., by entering “Pt - 2H” instead of Pt2+, where Pt means Pt0); 
- the software does not generate theoretical isotope patterns and does not 
consider experimental isotope patterns. No comparison between the theoretical 
and experimental isotope patterns is possible. The user must generate 
theoretical isotope patterns manually and compare those with experimental 
patterns that are claimed to contain metal ion(s) by the software based on 
searches for monoisotopic species only. The researcher also uses his/her 
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judgement to eliminate false positives or negatives. This visual analysis is 
always tedious and very time-consuming. 
Sequest has already been used for metalloproteomics purposes with the intent to locate 
metal binding sites [9,16,17]. Instead Mascot, the software we currently utilize in our 
laboratories for "classical" proteomics experiments, to the best of our knowledge, has 
never been used for binding site location of a metallo fragment on a protein. For this 
reason, we decided to test the applicability of Mascot in this specific 
metalloproteomics application. 
 
6.3.3 Binding site location in the CDDP-Cyt c model system through Mascot 
automated search followed by manual check 
First of all, we introduced in Mascot interface a customized database consisting only of 
the horse heart Cyt c sequence, thus deleting any possible statistic evaluation on the 
results.  
Among the variable modifications listed in paragraph 6.2.5, it is worth to linger over 
the platinated ones, i.e. [Pt]2+, [(NH3)Pt]2+, [(NH3)2Pt]2+ and [(NH3)2PtCl]+, the possible 
CDDP metallo fragments that can bind to proteins [9] (see fig. 6.2). Due to the high 
affinity of Pt(II) for the S-donors present in the amino acid side chains, it is reasonable 
to introduce C and M among the possible binding sites. However, N-donors, as H, K 
and W, and O-donors, as D, E, S, T and Y cannot be excluded a priori. It means a total 
of four platinated modifications on nine possible nucleophilic binding sites (S can be 
excluded since it is not present in horse heart Cyt c sequence). This elevated number of 
variable modifications turned out to be unmanageable by Mascot within just one search 
file, thus forcing us to create nine different search files, one for each of the possible 
binding sites. In this way, obviously, the presence of mixed bis- and tris-adducts 
(adducts where the two/three Pt centers are bound to two/three amino acids of different 
nature) is not revealed. However, we have to say that the presence of bis- and tris-
adducts in the starting material (see fig. 6.2) is quite irrelevant in comparison to the 
most intense mono-adduct peak.  
The results coming from Mascot automated search are simply based on the mass 
tolerance imposed in Mascot interface for the precursor peptide and its fragments. So, 
as anticipate in paragraph 6.3.2, all the platinated precursor peptides/fragments claimed 
by Mascot must be checked by manually generating the relative theoretical isotope 
pattern and comparing it with the corresponding experimental isotopic patterns of the 
precursor ion in the HR full scan or its fragments in the MS/MS spectra. To understand 
how the manual check works, let’s consider, as exemplificative case, one of the Mascot 
results coming from the automated assignment: the binding of [(NH3)Pt]2+ on Met65 
contained in the peptide 56-72. Fig. 6.4 shows the comparison between the 
experimental isotopic pattern of peptide 56-72 + [(NH3)Pt]2+ (a) and its theoretical 
simulation (b): the correspondence is excellent, both in terms of mass values 
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(monoisotopic mass error = 4.5 ppm) and isotopic profile shape (characteristic of the 
presence of one Pt atom). In the figure, it is also highlighted the monoisotopic mass 
value that Mascot uses to perform the assignment. 
 
Fig. 6.4 Comparison between a) the experimental isotopic pattern of peptide 56-72 + 
[(NH3)Pt]2+ (acquisition in Orbitrap) and b) its theoretical simulation. 
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A similar procedure was applied to verify the reliability of the attributions of all the 
twenty-one b and y fragment ions identified by Mascot and coming from the CID of 
peptide 56-72 + [(NH3)Pt]2+ on Met65. Only for explanatory purpose, we report in fig. 
6.5 the comparison between the experimental isotopic pattern of the claimed b13++ 
fragment ion of peptide 56-72 with [(NH3)Pt]2+ on Met65 (a) and its theoretical 
simulation (b). Mascot assignment is, in this case, a false positive. Despite that the 
error on the mass value used for the assignment (black circles in fig. 6.5) is within the 
tolerance imposed in Mascot interface, the isotopic profiles and the charge states are  
completely in disagreement. In fact, the species on the left doesn’t contain Pt and is 
mono-charged, while that on the right contains one Pt and is doubly-charged. 
Fig. 6.5 Comparison between a) the experimental isotopic pattern of the claimed b13++ 
fragment ion of peptide 56-72 + [(NH3)Pt]2+ on Met65 (acquisition in IT) and b) its 
theoretical simulation. 
 
Using the manual check, the reliability of the assignment for the remaining twenty 
fragment ions was tested and the number of correct attributions was thus reduced from 
twenty-one to eleven (fig. 6.6). 
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Fig. 6.6 Peptide 56-72 + [(NH3)Pt]2+ on Met65: the eleven correct Mascot b and y 
attributions after manual check. 
 
Among these attributions, only b6 and b10 resulted to be very informative fragments: in 
fact, b6 doesn’t contain Pt, while b10 does. It means that [(NH3)Pt]2+ modification must 
be within the ETLM portion of peptide 56-72 and, therefore, the metallo fragment can 
be placed on the S-donor Met65. However, Met65 is not the only one possible binding 
site in the ETLM portion: the E62 and T63 O-donors must be taken into account as 
additional potential binding sites. 
This ambiguous binding site attribution can be explain by considering that: 
1) a relative small number of b and y fragments was generated in CID spectra, 
probably due to the fact that Cyt c, in principle, can act as mono-, bi-, tri- and 
tetradentate ligand on CDDP (the simultaneous involvement of more than one 
binding site is possible), thus preventing an extensive fragmentation process;  
2) it is difficult to suppose a chromatographic separation for two peptides having 
the same sequence but being mono-platinated on two different amino acid 
residues, for example, the peptide 56-72 platinated on M65 or on E62 or on 
T63. As a consequence, in CID spectrum, the coexistence of fragments coming 
from all these peptides is possible. 
The above explained work methodology was applied to all the platinated peptides 
found by Mascot automated search relatively to the nine possible binding sites (M, C, 
D, E, H, K, T, W, Y; data not reported here): this manual check is a very time-
consuming process, but it is indispensable in order to guarantee the reliability of the 
proposed binding sites. 
After manual check, the final list of CDDP binding sites on Cyt c encompassed: T58, 
W59, K60, E61, E62, T63, M65, E66, Y67 and M80. From these results, it is possible 
to notice that only two different specific portions of the protein seem to be involved in 
the binding, namely peptide W59-Y67 and M80. Moreover, not all the possible donors 
present in the tryptic peptides 56-72 and 80-86 resulted involved in the binding (see 
It doesn’t contain Pt It contains Pt 
                                                                                                                            Chapter 6 
89 
 
E69, K72 and K86). Finally, not all the tested binding sites resulted to be binding sites 
(see C, H, D). All these findings revealed that our bottom-up approach was able to 
highlight the binding selectivity of CDDP on Cyt c, despite the elevate number of 
possible nucleophilic donors in the protein (four S-donors, twenty-three N-donors, 
twenty-six O-donors). 
In table 6.1 we compare our results with those present in the literature and already 
reported in paragraph 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1 Summary of CDDP-Cyt c binding sites, according to the literature and our 
experiment. I = our experiment; II = [1]; III = [3]; IV = [2]; V = [4]. In light blue = 
bottom-up MS experiments. In light green = XRD experiment. The references cited 
here are discussed in detail in paragraph 6.1. 
  EXPERIMENT 
  I II III IV V 
  
BINDING 
 
SITE 
H18    X  
H33    X  
T58 X     
W59 X     
K60 X     
E61 X  X  X 
E62 X  X   
T63 X  X   
M65 X X X X X 
E66 X     
Y67 X     
M80 X  X X  
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Discrepancies among the results of table 6.1 can be, at least in part, ascribed to 
different preparative/analytical conditions. In this frame, however, considering also the 
issue of the ambiguous binding site attribution, our results are in good agreement with 
the literature and Met65 can be confirmed again as the primary binding site of CDDP 
on Cyt c. 
Finally, we decided to investigate the 3D structure of the horse heart Cyt c present in 
the RSCB Protein Data Bank (ID 1AKK), in order to ascertain the real accessibility of 
the ten proposed binding sites. T58, K60, E61, E62, M65 and E66 resulted fully 
accessible, T63 only partially accessible while W59, Y67 and M80 not accessible. 
These results, added with those of table 6.1, together with the issue of the ambiguous 
binding site attribution and the fact that M80 is covalently involved in the binding with 
heme group, convinced us that probably it is more appropriate to exclude W59, Y67 
and M80 from the list of CDDP binding sites on Cyt c. 
 
6.3.4 Binding site location in the CDDP-HSA system through Mascot automated 
search followed by manual check 
The binding site search for the CDDP-HSA system was performed in an analogue way 
to that already explained for the CDDP-Cyt c system in the previous paragraph, with 
only three variations: 
1) serine was introduced among the possible binding sites of CDDP, since this 
amino acid is present in HSA sequence; 
2) for the automated search on digested HSA, some non-platinated variable 
modifications were introduced in Mascot interface, in accordance with what 
declared by the manufacturer of the protein (possible presence of 
cysteinylation on C, phosphorylation on S, T, Y and N-glycosylation on R and 
K); 
3) based on the results obtained for the digested HSA in the automated Mascot 
search followed by manual check, we introduced cysteinylation on C and N-
glycosylation on K among the other non-platinated variable modifications for 
the CDDP-HSA system. 
For the CDDP-HSA system, the same difficulties in manual re-processing of data and 
the same ambiguities in the attribution of binding sites were found, as for the CDDP-
Cyt c system. 
In table 6.2 we compare our results for the CDDP-HSA system with those present in 
the literature and already reported in paragraph 6.1. 
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Table 6.2 Summary of CDDP-HSA binding sites, according to the literature and our 
experiment. I = our experiment; II = [6]; III = [9]; IV = [11]; V = [3]; VI = [10]; VII = 
[12]. In light blue = bottom-up MS experiments. In apricot = NMR experiment. In light 
green = XRD experiment. The references cited here are discussed in detail in paragraph 
6.1. 
  EXPERIMENT 
  I II III IV V VI VII 
  
BINDING 
 
SITE 
D1 X       
H3 X       
K4 X       
S5 X       
E6 X       
H9 X     X  
D13      X  
C34   X     
H67    X  X X 
M87  X      
H105      X X 
C124    X    
H128    X  X  
Y148   X     
Y150   X     
H247    X  X X 
H288     X  X 
C289     X   
M298  X  X X X X 
M329   X  X X X 
H338     X   
D375   X     
E376   X     
M446  X      
H535       X 
M548   X    X 
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Having a look to columns from experiment II to experiment VII, it is possible to notice 
a certain degree of heterogeneity among the results presented in the literature: the 
identified binding sites in the different experiments are in poor agreement with each 
other, except probably for M298 and M329, thus indicating that the study of the 
location of Pt on HSA is not a trivial issue. Surprisingly, our results turned out to be 
even more out of trend: they suggested a binding in the N-terminal region of HSA (D1, 
H3, K4, S5, E6, H9), while the other results seem to show a more homogeneous 
binding all over the entire protein. Moreover, it has to be notice that, while the majority 
of the experiments indicates M and H as the most probable binding sites, our results, 
instead, propose a preponderance of O- and N-donors, but no methionine. 
The possible cause of the general discrepancies present in table 6.2 could be searched, 
first of all, in the different preparative/analytical conditions used in experiments I-VII. 
Moreover, the complexity and wide heterogeneity of the HSA, which makes difficult a 
safe identification of the variable modifications present in the starting material, can 
complicate automated search on metallated adducts. Regarding our specific results, we 
are confident we can exclude the detachment of Pt center from HSA during the bottom-
up MS approach (see discussion in paragraph 6.3.1) and, instead, we tentatively 
explained them by considering the inability of Mascot to find platinated cross-linked 
peptides, almost surely present in the HSA-CDDP system due to the high number of 
nucleophiles in human serum albumin. However, platinated cross-linked peptide search 
was taken into account only by Moraleja et al. in experiment VI [10], and it was 
manually accomplished.    
Despite the poor concordance of our findings with those present in the literature, we 
decided that it might be worth to take a look at the 3D structure of the HSA in the 
RSCB Protein Data Bank (ID: 4K2C), just to verify the real accessibility of the six 
binding sites we found. K4, E6 and H9 resulted fully accessible while S5 only partially 
accessible. D1 and H3 were not evaluated because, due to their high mobility, they are 
not included in the various HSA structures present in the RSCB Protein Data Bank. 
 
 
6.4 Conclusions and future perspectives 
 
Our first attempt to apply the FASP/bottom-up MS approach for cisplatin binding site 
location on Cyt c gave results in good agreement with those already present in the 
literature. The binding seems to involve two specific portions of the protein: M80 and 
peptide 58-67, in particular the amino acids T58, W59, K60, E61, E62, T63, M65, E66 
and Y67. After a check on the 3D structure of the horse heart Cyt c, in order to 
ascertain real accessibility of the found binding sites, and considering the fact that M80 
is covalently involved in the binding with heme group, the list of the potential binding 
sites was reduced to T58, K60, E61, E62, T63, M65 and E66. The FASP/bottom-up 
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approach demonstrated its capability to highlight the selective binding of CDDP to Cyt 
c, even though a certain degree of indeterminacy in the location of vicinal binding site 
persists, due to the intrinsic limitations of this technique (lack of an extensive 
fragmentation process and absence of chromatographic separation among the same 
peptide platinated on different positions). Our approach does not require, at least for 
single-protein samples, a pre-fractioning of platinated adducts/peptides, despite their 
poor ionization in ESI-MS [3,9,10]. Moreover, the methodology was developed in 
order to analyze low quantities of proteins (nanoLC-nanoESI analysis), thus offering 
the possibility to apply it to the survey of real biological samples. We believe that this 
approach can be extended, in a systematic way, to other simple, model systems 
endowed of the needed stability but, in our opinion, a comparison with the results 
coming from other analytical techniques (XRD, NMR) is always advisable. However, 
we have also to take into account that any possible discrepancies in the results, 
obtained with different techniques, may be attributed to the very different sample 
preparation/analytical conditions.  
Possible future experiments on the CDDP-Cyt c system could include: 
- the use of higher collision energy, hoping to obtain a more extended degree of 
fragmentation for platinated peptides. On the other hand, too high collision 
energies may lead to breakage of the Pt-peptide and Pt-ligand bonds; 
- targeted MS3 experiments on specific platinated fragments of proper intensity, 
as well as different methods of peptide fragmentation (for example ETD) or 
peptide separation (IMS), in order to solve ambiguous attributions of binding 
site location; 
- to try different incubation times and different CDDP/Cyt c ratios, with the aim 
to evaluate their correlation with the nature and the number of CDDP binding 
sites. 
 
The application of the FASP/bottom-up MS approach to the more complex system 
CDDP-HSA produced results which do not find a match with those reported in the 
literature. The possible causes of this discrepancy could be searched in the wide 
heterogeneity of the HSA starting material, which complicates Mascot automated 
search, as well as in the inability of the search engine to find platinated cross-linked 
peptides, almost surely present in the HSA-CDDP system due to the high number of 
nucleophiles in human serum albumin. This last issue, in particular, would require an 
additional manual search in addition to the manual check already performed on the 
claimed platinated peptides. In our opinion, for the CDDP-HSA system, a more 
detailed investigation is advisable before attempting to extend the method, in a 
systematic way, to other proteins of large size or mixtures of proteins from biological 
samples. Possible future studies might include middle-down approaches on CDDP-
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HSA adducts, as well as surveys on the incubation of CDDP with the three domains of 
HSA. 
 
Finally, regarding the very time-consuming manual check on the platinated peptides 
claimed by the search engine, two new tools were developed in the last year to help the 
researchers. The first, Polycut [18], is a computer program created at Melbourne 
University and it should be ready in a few months for free downloading. It was written 
to assist mass spectrometry-based bioinorganic studies via top-down and bottom-up 
approaches. It does automatic assignment of MSn signals by considering the entire 
experimental and simulated isotopic patterns of a metallated ion rather than reading 
only the mono-isotopic m/z values. The second, SNAP [19], is an algorithm pre-
programmed into the Data Analysis software by Bruker Daltonics. Similarly to 
Polycut, it allows the identification of metal-containing peptides in proteomic LC-MS 
and MS/MS data sets by considering their characteristic isotopic patterns. The re-
processing of our raw files with these two programs/algorithms would be very 
interesting, in order to verify the reliability of Mascot automated search followed by 
manual check in comparison with a fully automated search. 
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7. GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
In this PhD thesis, mass spectrometry-based approaches were used to characterize, at 
molecular level, the adducts formed between some metallodrugs (or novel, promising 
metal compounds) and several proteins. The obtained results can be profitably 
exploited for a more rational design of novel anticancer metallodrugs through a 
“mechanism oriented” approach. 
 
This aim was pursued through two main search directions: 
i) the study on the chemical nature and the binding stoichiometry of the adducts formed 
between small size proteins and: a) new analogues of cisplatin and oxaliplatin 
anticancer drugs (chapter 3); b) novel Au(III) complexes (chapter 4); 
ii) the development and introduction in our laboratories of an efficient and generally 
applicable method for metallodrugs binding site location on proteins, regardless of the 
MW and nature of the protein and the type of metal complex under investigation, in 
order to get closer to the study of real, interesting biological systems (chapters 5 and 
6). 
 
In the first phase of the thesis, the chemical and biological profiles of the novel 
complexes cisPtBr2 and PtI2(DACH) were studied in comparison to those of their 
precursors, respectively cisplatin and oxaliplatin. In particular, ESI-MS experiments 
showed the similarity of behavior between cisPtBr2 and CDDP in their binding to the 
model protein HEWL: Pt coordination involves the preferential detachment of halide 
ligands and the full retention of ammonia ligands. Instead, regarding the incubation of 
PtI2(DACH) with HEWL and RNase A, no metallodrug–protein adduct was detected in 
ESI-MS, this indicating that PtI2(DACH), in contrast to oxaliplatin, is not able to bind 
these model proteins. However, the two compounds showed a significant affinity for 
standard DNA oligonucleotides. Regardless of the differences and analogies of 
behavior highlighted by ESI-MS experiments, oxaliplatin and PtI2(DACH) induced 
roughly comparable cytotoxicity in three representative CRC cell lines. This implies 
that the replacement of oxalate with two iodide does not impair the cellular effects of 
oxaliplatin, that may be thus attributed mainly to the [Pt(DACH)]2+ chemical moiety. 
In the second phase, we studied the chemical and biological profiles of Au(III) 
complexes bearing chelating nitrogen/carbon donors or quinoline derivatives as N-/O-
donors. The ESI-MS results highlighted that the presence of a C-Au bond stabilizes the 
gold(III) center against reduction, in comparison with quinoline derivatives. Moreover, 
the use of a high resolution mass analyzer provided useful information about the 
mechanism of binding of these compounds to model proteins. Finally, MALDI-TOF 
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experiments pointed out the binding of the complex Aubipyc on the CXXC motif 
present in peptide 1-20 of the Atox1 protein.  
The valuable information, obtained in chapters 3 and 4 thanks to the use of the Orbitrap 
high resolution mass analyzer, are strictly circumscribed to proteins of small size. The 
studies here described could be extended to proteins of larger size by exploiting state-
of-the-art instruments, able to routinely deal with biomolecules of higher MW. For 
examples, the use of Q-TOF or Q-Orbitrap mass analyzers might introduce us to the 
study of bigger and more relevant biological systems. 
 
In the third phase, we have designed a general and systematic protocol to test, a priori, 
the stability of metallodrug-protein adducts under the typical conditions of the 
FASP/bottom-up mass spectrometry approach, being this latter the methodology we 
chose for the binding site location studies described in phase four. This protocol may 
turn helpful to scientists working in the field of metalloproteomics and investigating 
metallodrug-protein interactions. The protocol developed constitutes a useful and 
almost complete track to be followed but it is obviously open to additions and 
improvements, according to the chosen MS instrument and the applied sample 
preparation procedures. The protocol was specifically applied to two representative 
model systems, the more investigated Cyt c-CDDP adducts and the less studied Cyt c-
RAPTA-C ones. The results we obtained showed that Cyt c-CDDP adducts were stable 
in all tested conditions, while Cyt c-RAPTA-C adducts manifested a remarkable 
instability in the 50 mM ammonium bicarbonate buffer (the buffer used during the 
tryptic digestion step). This latter finding demonstrates the advisability to perform a 
test-protocol like this when starting any bottom-up MS investigation on protein-
metallodrug systems, especially with novel, or scarcely studied, metal complexes. In 
fact, the nature of the metal, of its ligands and of the protein microenvironment are 
variables that may undoubtedly affect the stability of the metal-protein coordination 
bond during the bottom-up approach, and are not easy to predict. 
 
Finally, in the fourth phase of the thesis, we applied, for the first time in our 
laboratories, the FASP/bottom-up MS approach for cisplatin binding site location on 
the model protein Cyt c and the actual target protein HSA. 
For the CDDP-Cyt c system we obtained results in good agreement with those already 
present in the literature and, after a check on the 3D structure of the horse heart Cyt c, 
the proposed binding sites were T58, K60, E61, E62, T63, M65 and E66. The 
FASP/bottom-up approach demonstrated its capability to highlight the selective 
binding of CDDP to Cyt c, even though a certain degree of indeterminacy in the 
location of vicinal binding site persists, due to the intrinsic limitations of this 
technique, as the lack of an extensive fragmentation process and the absence of 
chromatographic separation among the same peptide platinated on different positions. 
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The issue of the ambiguous attributions could be overcome by using a higher collision 
energy during CID in IT, targeted MS3 experiments on specific platinated fragments of 
proper intensity and different methods of peptide fragmentation (for example ETD) or 
peptide separation (IMS). Our approach does not require, at least for single-protein 
samples, a pre-fractioning of platinated adducts/peptides, despite their poor ionization 
in ESI-MS. Moreover, the methodology was developed in order to analyze low 
quantities of proteins (nanoLC-nanoESI analysis), thus offering the possibility to apply 
it to the survey of real biological samples. We believe that this approach can be 
extended, in a systematic way, to other simple model systems endowed of the needed 
stability but, in our opinion, a comparison with the results coming from other analytical 
techniques (XRD, NMR) is always advisable. However, we have also to take into 
account that any possible discrepancies in the results, obtained with different 
techniques, may be attributed to the very different sample preparation/analytical 
conditions. 
The application of the FASP/bottom-up MS approach to the more complex system 
CDDP-HSA produced results which do not find a match with those reported in the 
literature, already poorly concordant with each other. The possible causes of this 
discrepancy could be searched in the wide heterogeneity of the HSA starting material, 
which complicates Mascot automated search, as well as in the inability of the search 
engine to find platinated cross-linked peptides, almost surely present in the HSA-
CDDP system due to the high number of nucleophiles in human serum albumin. This 
last issue, in particular, would require an additional manual search in addition to the 
manual check already performed on the claimed platinated peptides. In our opinion, a 
more detailed investigation on the CDDP-HSA system is advisable before attempting 
to extend the methodology, in a systematic way, to other proteins of large size or 
mixtures of proteins from biological samples. Possible future studies might include 
middle-down approaches on CDDP-HSA adducts, as well as surveys on the incubation 
of CDDP with the three domains of HSA. 
Regarding the very time-consuming manual check on the platinated peptides claimed 
by the search engine, two new tools were developed in the last year to help the 
researchers: the computer program Polycut and the algorithm SNAP. They both do 
automatic assignment of MSn signals by considering the entire experimental and 
simulated isotopic patterns of a metallated ion rather than reading only the mono-
isotopic m/z values. The re-processing of our raw files with Polycut or SNAP would be 
very interesting, in order to verify the reliability of Mascot automated search followed 
by manual check in comparison with a fully automated search. 
 
Concluding, ESI-HRMS confirmed to be a valuable ally for the molecular 
characterization of the adducts formed between metallodrugs and relatively small, 
model proteins. Instead, metalloproteomics studies involving proteins of larger size, 
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might be better faced out with new generation hybrid HR mass spectrometers. In 
parallel, this must be accompanied by the development of software tools more 
specifically designed for the analysis of these complex data. 
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